65. 原発性免疫不全症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
16, Cutaquig
Ottawa Hospital Research Institute
2018 Phase 4 NCT03677557 Canada;
2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID
IntraBio Ltd
2020 Phase 2 EUCTR2018-004407-39-DE Germany;Spain;United Kingdom;United States;
36-482-Hyaluronoglucosaminidase PH20 (rHuPH20)
Baxter Innovations GmbH
2012 - EUCTR2012-000481-38-GB Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
A10BK03
Cliniques universitaires Saint-Luc
2019 Phase 4 EUCTR2018-004191-35-BE Belgium;
ADA PBSC
National Human Genome Research Institute (NHGRI)
1990 - NCT00001255 United States;
ADA Umbilical Cord Blood Cells
National Human Genome Research Institute (NHGRI)
1990 - NCT00001255 United States;
ADA gene transfer
Donald B. Kohn, M.D.
2008 Phase 2 NCT00794508 United States;
AProArt
University of California, San Francisco
2018 Phase 1/Phase 2 NCT03538899 United States;
AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR
GENETHON
2013 - EUCTR2012-000242-35-DE France;Germany;Switzerland;United Kingdom;
Genethon
2013 Phase 1;Phase 2 EUCTR2012-000242-35-GB France;Germany;Switzerland;United Kingdom;
Abatacept
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT04925375 United States;
Emory University
2014 Phase 1 NCT01917708 United States;
Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
2016 Phase 2 EUCTR2015-002491-24-DE Germany;
Acoziborole
Drugs for Neglected Diseases
2021 Phase 2/Phase 3 NCT05256017 Congo, The Democratic Republic of the;Guinea;
Acoziborole (SCYX-7158)
Drugs for Neglected Diseases
2016 Phase 2/Phase 3 NCT03087955 Congo, The Democratic Republic of the;Guinea;
Adagen
Leadiant Biosciences, Inc.
2014 Phase 3 NCT01420627 United States;
Administration of drug (Interferon-gamma 1-b) subcutaneously
University of Colorado, Denver
2016 Phase 1 NCT02609932 United States;
Adverse Reactions of Gammagard subcutaneously at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subcutaneously at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subcutaneously at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subdermally at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subdermally at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subdermally at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Alefacept
Emory University
2010 - NCT01319851 United States;
Alemtuzumab
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2012 - NCT01652092 United States;
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2019 Early Phase 1 NCT03910452 United States;
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Alentuzumab (Campath)
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02629120 United States;
Allo BMT
National Cancer Institute (NCI)
2015 Phase 2 NCT02579967 United States;
Allogeneic Bone Marrow Transplantation
Fairview University Medical Center
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00358657 United States;
1997 Phase 1 NCT00008450 United States;
Allogeneic HSC
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
Allogeneic HSCT
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Allogeneic bone marrow transplantation
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2005 Phase 1 NCT00295971 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Allogeneic hematopoietic stem cell transplantation
Fairview University Medical Center
2000 - NCT00006056 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2005 Phase 1 NCT00295971 United States;
Allogeneic peripheral blood stem cell
National Institute of Allergy and Infectious Diseases (NIAID)
2019 Early Phase 1 NCT03910452 United States;
Anti-CD45
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2000 Phase 2/Phase 3 NCT00176878 United States;
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Anti-thymocyte globulin (rabbit)
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
Antithymocyte globulin
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
Argininhydrochlorid
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Asceniv™
ADMA Biologics, Inc.
2022 Phase 4 NCT05070455 -
Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
2012 Phase 1;Phase 2 EUCTR2010-024253-36-GB United Kingdom;
Autologous CD34+ cell transduced with G2SCID vector
David Williams
2018 Phase 1/Phase 2 NCT03311503 United Kingdom;United States;
Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy
GENETHON
- Phase 1;Phase 2 EUCTR2009-011152-22-FR France;
Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Orchard Therapeutics
2019 - NCT04049084 United Kingdom;United States;
B-Lymphocyte Stimulator (BLyS)
National Cancer Institute (NCI)
2001 Phase 1 NCT00024934 United States;
BMS-188667
Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
2016 Phase 2 EUCTR2015-002491-24-DE Germany;
BPX-501 T cells
Bellicum Pharmaceuticals
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
BT090
Biotest AG
2010 - EUCTR2010-019249-25-HU Germany;Hungary;
2010 - EUCTR2010-019249-25-DE Germany;Hungary;
BT524
Biotest AG
2013 Phase 1;Phase 2 EUCTR2011-004154-25-IT Egypt;Germany;Italy;Lebanon;
BT595
Biotest AG
2017 Phase 3 EUCTR2015-003652-52-GB Germany;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-ES Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-DE Germany;Russian Federation;Spain;United Kingdom;United States;
BT681
Biotest AG
2005 - EUCTR2004-004465-15-HU Germany;Hungary;
2005 - EUCTR2004-004465-15-DE Germany;Hungary;
BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
Baclofen
Johns Hopkins University
2007 Early Phase 1 NCT00640003 United States;
Bacteriophage
National Institute of Allergy and Infectious Diseases (NIAID)
1999 Phase 2 NCT00001145 United States;
Benznidazole
Population Health Research Institute
2004 Phase 3 NCT00123916 Argentina;Bolivia;Brazil;Canada;Colombia;El Salvador;
Universidad Autónoma de Bucaramanga
2015 Phase 2/Phase 3 NCT02369978 Colombia;
Biological sampling
Imagine Institute
2015 - NCT02909244 France;
Bivigam
ADMA Biologics, Inc.
2016 - NCT03037359 United States;
Blood Draw
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Blood Sample
Koneti Rao
2008 Phase 1/Phase 2 NCT00605657 United States;
Busilvex
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
medac Gesellschaft fuer klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-AT Austria;Czech Republic;Germany;Italy;Poland;
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-DE Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-CZ Austria;Czech Republic;Germany;Italy;Poland;
medac GmbH
2015 Phase 2 NCT02349906 Austria;Czech Republic;Czechia;Germany;Italy;Poland;
2015 - EUCTR2013-005508-33-IT Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-PL Austria;Czech Republic;Germany;Italy;Poland;
Busulfan
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1/Phase 2 NCT03765632 United Kingdom;
2012 Phase 1/Phase 2 NCT01380990 United Kingdom;
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
2000 Phase 2/Phase 3 NCT00176878 United States;
Michael Pulsipher, MD
2018 Phase 2 NCT03619551 United States;
National Center for Child Health and Development
2017 - JPRN-UMIN000030647 Japan;
2016 - JPRN-UMIN000022688 Japan;
National Center for Child Heath and Development
2018 Phase 1,2 JPRN-UMIN000030806 Japan;
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
2019 Early Phase 1 NCT03910452 United States;
2014 Phase 1/Phase 2 NCT02282904 United States;
2012 Phase 1/Phase 2 NCT03315078 United States;
2012 Phase 1/Phase 2 NCT01306019 United States;
Orchard Therapeutics
2016 Phase 1/Phase 2 NCT02999984 United States;
2013 Phase 1/Phase 2 NCT01852071 United States;
Sakaguchi Hirotoshi
2018 Phase 2 JPRN-jRCTs031180398 Japan;None (Japan only);
Seoul National University Hospital
2011 Phase 1/Phase 2 NCT01338675 Korea, Republic of;
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
2016 Phase 1/Phase 2 NCT01512888 United States;
University of California, San Francisco
2018 Phase 1/Phase 2 NCT03538899 United States;
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Busulfan IV
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02629120 United States;
Busulfan test dose
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Busulfan, Cyclophosphamide, ATG, GCSF
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Busulfan, Fludarabine and ATG
Emory University
2004 Phase 1/Phase 2 NCT00228852 United States;
Busulfan, Fludarabine, ATG, TLI
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
C1 ESTERASE INHIBITOR (HUMAN)
Octapharma Pharmazeutika Produktionsges.m.b.H.
2020 Phase 2 EUCTR2019-001693-28-DE Belarus;Germany;Russian Federation;Ukraine;
C1 Esterase Inhibitor Human
Octapharma Pharmazeutika Produktionsges.m.b.H.
2020 Phase 2 EUCTR2019-001693-28-DE Belarus;Germany;Russian Federation;Ukraine;
C1 inhibitor
HAE Global Registry Foundation
2017 - NCT03828279 Italy;
C1 inhibitor concentrate
Sanquin
2005 Phase 2 NCT00119431 Netherlands;
C1-esterase inhibitor [recombinant] (C1-INH-R)
IMMUNOe Research Centers
2018 Phase 4 NCT03576469 United States;
CD3/CD19 neg allogeneic BMT
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1/Phase 2 NCT03330795 United States;
CD3/CD19 negative allogeneic hematopoietic stem cells
Paul Szabolcs
2013 Phase 1/Phase 2 NCT01852370 United States;
CD34 Stem Cell Selection Therapy
Diane George
2013 Phase 1/Phase 2 NCT01966367 United States;
CD34+
Children's Hospital Medical Center, Cincinnati
2010 Phase 2 NCT01856582 United States;
CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT
National Institute of Allergy and Infectious Diseases (NIAID)
2012 Phase 1/Phase 2 NCT03315078 United States;
CD34+ cells transduced with ADA retrovir
National Human Genome Research Institute (NHGRI)
2001 Phase 1 NCT00018018 United States;
CD34+CELLS
Rocket Pharmaceuticals, Inc.
2020 Phase 1;Phase 2 EUCTR2020-000517-33-GB Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2018-002680-26-ES Spain;
CDZ173
NOVARTIS PHARMA SERVICES AG
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IT Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Novartis Pharma Services AG
2021 Phase 2;Phase 3 EUCTR2016-000468-41-FR Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2016-000468-41-GB Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-NL Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-CZ Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Novartis Pharmaceuticals
2015 Phase 2/Phase 3 NCT02435173 Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Pharming Technologies B.V.
- Phase 2;Phase 3 EUCTR2016-000468-41-DE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
CL20-i4-EF1a-h?c-OPT
St. Jude Children's Research Hospital
2016 Phase 1/Phase 2 NCT01512888 United States;
CT Scan
Koneti Rao
2008 Phase 1/Phase 2 NCT00605657 United States;
CUTAQUIG
Octapharma
2019 Phase 3 NCT03939533 United States;
CUVITRU
Baxalta now part of Shire
2018 - NCT03716700 Canada;
Campath -1H
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
Campath 1H
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
Campath, Fludarabine, Cyclophosphamide
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Catapresan 75, Tabletten
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Cell processing for TCRabeta+/CD19+ depletion
Michael Pulsipher, MD
2018 Phase 2 NCT03619551 United States;
Cell processing for TCRaß+/CD19+ depletion
Michael Pulsipher, MD
2018 Phase 2 NCT03619551 United States;
Chemotherapy, intrathecal chemotherapy, steroid therapy
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Chrono Super PID then Generic Syringe-Gammanorm
Octapharma
2015 Phase 4 NCT02503293 Australia;Germany;Italy;United Kingdom;
CliniMACS
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
CliniMACS® CD34 Reagent System cell sorter device
University of California, San Francisco
2018 Phase 1/Phase 2 NCT03538899 United States;
CliniMacs
St. Jude Children's Research Hospital
2016 Phase 1/Phase 2 NCT01512888 United States;
Clonidinhydrochlorid
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Collection of samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Conjugated pneumococcal vaccine (Prevenar)
Institute of Child Health
2006 Phase 3 NCT00656409 United Kingdom;
Continuous Glucose Monitor
Washington University School of Medicine
2020 - NCT04275479 United States;
Cryopreserved EFS-ADA LV transduced patient CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2018 Phase 1 EUCTR2018-000673-68-GB United Kingdom;
Cultured Thymus Tissue
M. Louise Markert
2010 - NCT01220531 United States;
Cultured Thymus Tissue Implantation (CTTI)
M. Louise Markert
2004 Phase 2 NCT00576836 United States;
Cultured Thymus Tissue for Implantation (CTTI)
M. Louise Markert
2005 Phase 1/Phase 2 NCT00579527 United States;
1991 Phase 2 NCT00576407 United States;
Cuvitru
Baxalta now part of Shire
2017 Phase 4 NCT03116347 Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
Cuvitru 200 mg/ml solution for subcutaneous injection
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Cyclophosphamide
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Capital Research Institute of Pediatrics
2015 - NCT03198195 -
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00358657 United States;
Graduate Schoool,Dept. of Community Pediatrics,Perinatal and Maternal Medicine,Tokyo Medical and Dental University
2015 - JPRN-UMIN000019532 Japan;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2012 - NCT01652092 United States;
2007 Phase 2/Phase 3 NCT00455312 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2019 Early Phase 1 NCT03910452 United States;
2015 Phase 1/Phase 2 NCT02629120 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Cyclophosphamide (Cytoxan)
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Cyclophosphamide 30
Columbia University
2002 Phase 2/Phase 3 NCT01019876 United States;
Cyclophosphamide 40
Columbia University
2002 Phase 2/Phase 3 NCT01019876 United States;
Cyclophosphamide Dose Level 1
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 2
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 3
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 4
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide post transplant
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 1/Phase 2 NCT02282904 United States;
Cyclosporine
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
1997 Phase 1 NCT00008450 United States;
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Cyclosporins
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
DB289
Immtech Pharmaceuticals, Inc
2003 Phase 2 NCT00803933 Congo;
2001 Phase 2 NCT00802594 Angola;Congo;
DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
ERYDEL S.P.A.
2016 Phase 3 EUCTR2015-005241-31-IT Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
EryDel S.p.A.
2020 Phase 3 EUCTR2018-000338-36-NO Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
2020 Phase 3 EUCTR2018-000338-36-GB Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000338-36-ES Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000338-36-DE Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000338-36-BE Australia;Belgium;Germany;India;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2015-005241-31-NO Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005241-31-ES Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005241-31-DE Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005241-31-BE Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
- Phase 3 EUCTR2018-000338-36-PL Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
- Phase 3 EUCTR2015-005241-31-PL Australia;Belgium;Costa Rica;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
Daclizumab
M. Louise Markert
2005 Phase 1/Phase 2 NCT00579527 United States;
Danazol
Boston Children's Hospital
2009 Phase 1/Phase 2 NCT01001598 United States;
The University of Queensland
2021 Phase 2 NCT04638517 Australia;
Data collection
Paul Szabolcs
2020 - NCT04528355 United States;
Depletion in CD45RA graft donor
Assistance Publique - Hôpitaux de Paris
2016 Phase 2 NCT02737384 France;
Dexametasone Fosfato Sodico
ERYDEL S.P.A.
2016 Phase 3 EUCTR2015-005241-31-IT Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
Dexamethasone 21-dihydrogen phosphate
Universitätsklinikum Heidelberg
2006 Phase 3 EUCTR2005-003201-81-DE Germany;
Dexamethasone sodium phosphate (soluzione 25mg/ml)
ERYDEL S.P.A.
2021 Phase 3 EUCTR2018-000338-36-IT Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
Dexamethasone, procarbazine
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Dextrose, in Water
Grifols Therapeutics Inc.
2002 Phase 3 NCT00220766 Canada;United States;
Donor peripheral blood stem cells.
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 1/Phase 2 NCT02282904 United States;
Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
EDS-EP dose range of ~14-22 mg DSP/infusion
Erydel
2017 Phase 3 NCT02770807 Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
EDS-EP dose range of ~5-10 mg DSP/infusion
Erydel
2017 Phase 3 NCT02770807 Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2012 Phase 1;Phase 2 EUCTR2010-024253-36-GB United Kingdom;
EF1aS-ADA lentiviral vector transduced patient CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2012 Phase 1;Phase 2 EUCTR2010-024253-36-GB United Kingdom;
EP2006 (Filgrastim)
Sandoz GmbH
2011 - EUCTR2011-001118-32-DE Germany;Sweden;
EZN-2279
Leadiant Biosciences, Inc.
2014 Phase 3 NCT01420627 United States;
Efficacy of Gammagard subcutaneously at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subcutaneously at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subcutaneously at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subdermally at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subdermally at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subdermally at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Eflornithine
Drugs for Neglected Diseases
2012 Phase 2/Phase 3 NCT01685827 Central African Republic;Congo;Congo, The Democratic Republic of the;
2004 Phase 3 NCT00146627 Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;
Eflornithine plus Nifurtimox combination therapy
Epicentre
2002 Phase 2/Phase 3 NCT00489658 Uganda;
Elapegademase-lvlr
Chiesi Farmaceutici S.p.A.
2019 - NCT03878069 United States;
Eltrombopag
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT04371939 Russian Federation;
Empagliflozin
Cliniques universitaires Saint-Luc
2019 Phase 4 EUCTR2018-004191-35-BE Belgium;
Hong Kong Children's Hospital
2021 - NCT04986735 -
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 1 NCT05078879 United States;
Estradiolvalerat
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Etoposide
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Etoposide, cytarabine, mercaptopurine
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
National Institute of Allergy and Infectious Diseases (NIAID)
2012 Phase 1/Phase 2 NCT01306019 United States;
FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
Fansidar (pyrimethamine and sulfadoxine)
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 1 NCT00013689 United States;
Fexinidazole
Drugs for Neglected Diseases
2019 Phase 2/Phase 3 NCT03974178 Malawi;Uganda;
2016 Phase 3 NCT03025789 Congo, The Democratic Republic of the;Guinea;
2015 Phase 1 NCT02571062 France;
2014 Phase 2/Phase 3 NCT02184689 Congo, The Democratic Republic of the;
2014 Phase 2/Phase 3 NCT02169557 Congo, The Democratic Republic of the;
2014 Phase 2 NCT02498782 Bolivia;
2012 Phase 2/Phase 3 NCT01685827 Central African Republic;Congo;Congo, The Democratic Republic of the;
2009 Phase 1 NCT00982904 France;
Fibrinogen (coagulation factorI)
CSL Behring GmbH
2011 - EUCTR2007-004088-22-DE Germany;Italy;
Fibrinogen Concentrate from Human Plasma
Biotest AG
2013 Phase 1;Phase 2 EUCTR2011-004154-25-IT Egypt;Germany;Italy;Lebanon;
Filgrastim
Fairview University Medical Center
2000 - NCT00006056 United States;
National Center for Research Resources (NCRR)
1994 Phase 2 NCT00004787 -
Filgrastim Hexal
Sandoz GmbH
2011 - EUCTR2011-001118-32-DE Germany;Sweden;
Filgrastim, Alemtuzumab
St. Jude Children's Research Hospital
2004 Phase 1 NCT00152100 United States;
Flebogamma DIF
Instituto Grifols, S.A.
2008 Phase 4 NCT00634569 United States;
Fludarabina Accord
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Fludarabine
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
2004 Phase 2 NCT00578643 United States;
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
Columbia University
2002 Phase 2/Phase 3 NCT01019876 United States;
Graduate Schoool,Dept. of Community Pediatrics,Perinatal and Maternal Medicine,Tokyo Medical and Dental University
2015 - JPRN-UMIN000019532 Japan;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2007 Phase 2/Phase 3 NCT00455312 United States;
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
National Center for Child Heath and Development
2018 Phase 1,2 JPRN-UMIN000030806 Japan;
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 1/Phase 2 NCT02282904 United States;
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
Fludarabine Phosphate
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00358657 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Fludarabine monophosphate
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Fludarabine phosphate
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2005 Phase 1 NCT00295971 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Fludarabine, Busulfan, Thymoglobulin
The Korean Society of Pediatric Hematology Oncology
2007 Phase 1/Phase 2 NCT00885833 Korea, Republic of;
Fludarabine, Melphalan, Thiotepa
St. Jude Children's Research Hospital
2005 Phase 1 NCT00160355 United States;
Fortecortin Inject 40 mg Amp.
Universitätsklinikum Heidelberg
2006 Phase 3 EUCTR2005-003201-81-DE Germany;
G-CSF
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
2014 Phase 2/Phase 3 NCT02231879 United States;
G-CSF for Conditioning before HSCT.
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2016 Phase 2 NCT03019809 Russian Federation;
G1XCG
Johann Wolfgang Goethe-University
2013 Phase 1;Phase 2 EUCTR2012-001725-26-DE Germany;
G1XCGD transduced CD34+ cells
GENETHON
2013 - EUCTR2012-000242-35-DE France;Germany;Switzerland;United Kingdom;
Genethon
2013 Phase 1;Phase 2 EUCTR2012-000242-35-GB France;Germany;Switzerland;United Kingdom;
GAMMAGARD LIQUID
Baxalta now part of Shire
2017 Phase 3 NCT03277313 United States;
GAMUNEX-C
Grifols Therapeutics Inc.
2011 Phase 4 NCT01465958 United States;
GTG003.08
GENETHON
- Phase 1;Phase 2 EUCTR2009-011152-22-FR France;
GVHD Prophylaxis
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
2015 Phase 2 NCT02579967 United States;
Gadolinium For abdomen
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Gadolinium For lower back
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Gammagard S/D (Solvent/Detergent)
Baxalta now part of Shire
2002 Phase 2 NCT00161993 Finland;Sweden;
Gammaglobulin
Federal University of São Paulo
2002 - NCT00661401 Brazil;
Gammanorm
Octapharma
2014 Phase 4 NCT02180763 France;
Gammanorm 165 mg/mL
Octapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria
2015 Phase 3;Phase 4 EUCTR2014-003746-27-GB Australia;Germany;United Kingdom;
2015 Phase 3;Phase 4 EUCTR2014-003746-27-DE Australia;Germany;Italy;United Kingdom;
Gammaplex
Bio Products Laboratory
2011 Phase 4 NCT01289847 Chile;Israel;United States;
Bio Products Laboratory Limited
- - EUCTR2011-005679-18-Outside-EU/EEA Chile;United States;
Gammaplex ()
Bio Products Laboratory
2014 Phase 3 NCT01963143 Hungary;United Kingdom;United States;
Gammaplex (Intravenous immunoglobulin)
Bio Products Laboratory
2006 Phase 3 NCT00278954 United States;
Gammaplex 10
Bio Products Laboratory
2014 Phase 3 NCT01963143 Hungary;United Kingdom;United States;
Bio Products Laboratory Limited
2014 Phase 3 EUCTR2013-002290-21-HU Hungary;United Kingdom;United States;
2014 Phase 3 EUCTR2013-002290-21-GB Hungary;Israel;United Kingdom;United States;
Gamunex-C
Grifols Therapeutics LLC
2020 Phase 3 NCT04561115 United States;
Gcsf
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT03547830 Russian Federation;
Gene Therapy Method for CGD
National Institute of Allergy and Infectious Diseases (NIAID)
1995 Phase 1 NCT00001476 United States;
Gene transfer
David Williams
2010 Phase 1/Phase 2 NCT01129544 United States;
Gene-Transduced Autologous CD34+ Stem Cells
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 1 NCT00028236 United States;
Generic Syringe then Chrono Super PID-Gammanorm
Octapharma
2015 Phase 4 NCT02503293 Australia;Germany;Italy;United Kingdom;
Genetically modified autologous blood stem cells
Johann Wolfgang Goethe-University
2013 Phase 1;Phase 2 EUCTR2012-001725-26-DE Germany;
Glycolic acid
University of Pennsylvania
2009 - NCT01289171 Botswana;
Glycosade
John Mitchell
2013 - NCT02054832 Canada;
Gold
Chengdu Women's and Children's Center Hospital
2021 Phase 0 ChiCTR2100043049 China;
Children's Hospital of Chongqing Medical University
2020 Phase 0 ChiCTR2000032139 China;
Gp91 Grans
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1 NCT05189925 United States;
Granulocyte colony stimulating factor (G-CSF)
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
HTLP
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 1;Phase 2 EUCTR2018-001029-14-FR France;
HUMAN NORMAL IMMUNOGLOBULIN (IV)
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Biotest AG
2017 Phase 3 EUCTR2015-003652-52-GB Germany;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-ES Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-DE Germany;Russian Federation;Spain;United Kingdom;United States;
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2010-023483-41-FR France;Hungary;
2011 - EUCTR2010-023483-41-HU Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
2009 - EUCTR2009-012036-32-FR France;
- - EUCTR2010-023483-41-Outside-EU/EEA Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
Haemocomplettan P
CSL Behring GmbH
2007 - EUCTR2006-006023-39-IT Italy;
Haemocomplettan(R) P 1g/2g
CSL Behring GmbH
2011 - EUCTR2007-004088-22-DE Germany;Italy;
Haplo BM with T cell depletion
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Haploidentical Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
2020 Phase 2 NCT04414046 United States;
Hematopoetic Stem Cell Transplantation
University of Pittsburgh
2012 - NCT03333200 United States;
Hematopoietic Stem Cell Transplant
Medical College of Wisconsin
2013 Phase 2 NCT01998633 Canada;United States;
Hematopoietic stem cell transplantation
St. Jude Children's Research Hospital
2005 Phase 1 NCT00160355 United States;
Hizentra
CSL Behring LLC
- Phase 4 EUCTR2016-003799-33-Outside-EU/EEA Canada;United States;
University of South Florida
2010 - NCT01354587 United States;
Hizentra®
CSL Behring
- - EUCTR2014-003609-14-Outside-EU/EEA Japan;
- - EUCTR2014-003608-61-Outside-EU/EEA Japan;
- - EUCTR2014-003409-13-Outside-EU/EEA Japan;
CSL Behring AG
2008 Phase 3 EUCTR2008-000830-30-GB France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
- - EUCTR2014-003607-30-Outside-EU/EEA United States;
- - EUCTR2014-003605-15-Outside-EU/EEA United States;
Horse -Anti-thymocyte
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
Human Fibrinogen Concentrate
Biotest AG
2013 Phase 1;Phase 2 EUCTR2011-004154-25-IT Egypt;Germany;Italy;Lebanon;
Human Immunglobulin G (IgG)
CSL Behring AG
2007 Phase 3 EUCTR2006-006745-13-GB France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-FR France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-ES France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-SE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-DE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
Human Immunoglobulin
KEDRION S.P.A
2021 Phase 3 EUCTR2020-001496-32-PT Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-SK Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-HU Hungary;Italy;Portugal;Russian Federation;Slovakia;
Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01412385 Austria;Germany;Hungary;Sweden;United Kingdom;
Human Normal Immunoglobulin G (IgG > purity)
CSL Behring AG
- - EUCTR2014-003772-23-Outside-EU/EEA United States;
Human Normal Immunoglobulin for Subcutaneous Administration
CSL Behring
2006 Phase 3 NCT00419341 United States;
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
CSL Behring
2007 Phase 3 NCT00542997 France;Germany;Italy;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
Human Normal Immunoglobulin for subcutaneous administration
LFB Biotechnologies
2014 - EUCTR2013-000620-34-GB France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-IT France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-HU France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-DE France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
Human T Lymphoid Progenitor (HTLP) injection
Assistance Publique - Hôpitaux de Paris
2020 Phase 1/Phase 2 NCT03879876 France;
Human normal immunoglobulin
UMC Utrecht
2021 Phase 4 EUCTR2021-005001-26-NL Netherlands;
Human normal immunoglobulin (IVIg)
Biotest AG
2005 - EUCTR2004-004465-15-HU Germany;Hungary;
2005 - EUCTR2004-004465-15-DE Germany;Hungary;
Human normal immunoglobulin (subcutaneous)
CSL Behring LLC
- Phase 4 EUCTR2016-003799-33-Outside-EU/EEA Canada;United States;
Human normal immunoglobulin for intravenous administration
LFB SA
2007 - EUCTR2007-001410-17-FR France;
Human normal immunoglobulin for intravenous use (IVIG)
Biotest AG
2010 - EUCTR2010-019249-25-HU Germany;Hungary;
2010 - EUCTR2010-019249-25-DE Germany;Hungary;
HyQvia 100 mg/ml solution for infusion for subcutaneous use
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Hydroxyurea
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
I10E
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2010-023483-41-FR France;Hungary;
2011 - EUCTR2010-023483-41-HU Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
- - EUCTR2010-023483-41-Outside-EU/EEA Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
IB 1001
IntraBio Ltd.
2019 Phase 2 EUCTR2018-004407-39-GB Germany;United Kingdom;United States;
IB1001
IntraBio Inc
2020 Phase 2 NCT03759678 Germany;Spain;United Kingdom;United States;
IntraBio Ltd
2020 Phase 2 EUCTR2018-004407-39-DE Germany;Spain;United Kingdom;United States;
IFN-gamma
National Institute of Allergy and Infectious Diseases (NIAID)
2010 Phase 4 NCT01147042 United States;
IGIV,
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
IGIV-C
Grifols Therapeutics LLC
2016 Phase 3 NCT02604810 Canada;United States;
IGNG
LFB BIOTECHNOLOGIES
2009 - EUCTR2009-012036-32-FR France;
LFB SA
2007 - EUCTR2007-001410-17-FR France;
IGSC
Grifols Therapeutics LLC
2021 Phase 4 NCT04566692 United States;
2016 Phase 3 NCT02806986 Australia;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 NCT02604810 Canada;United States;
IGSC daily push versus 2 times per week pump
Grifols Therapeutics LLC
2019 Phase 3 NCT03814798 United States;
IGSC daily push versus every 2 weeks pump
Grifols Therapeutics LLC
2019 Phase 3 NCT03814798 United States;
IGSC daily push versus once a week pump
Grifols Therapeutics LLC
2019 Phase 3 NCT03814798 United States;
IGSC infusion
Takeda
2021 Phase 3 NCT04842643 Japan;
IGSC,
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
IMMUNOGLOBULIN G
CSL Behring
2008 Phase 3 EUCTR2006-006745-13-PL France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
OCTAPHARMA AG
2012 - EUCTR2012-000792-16-HU Czech Republic;Germany;Hungary;
2012 - EUCTR2012-000792-16-DE Czech Republic;Germany;Hungary;
2012 - EUCTR2012-000792-16-CZ Czech Republic;Germany;Hungary;
Octapharma AG
- - EUCTR2011-005015-82-Outside-EU/EEA United States;
IMMUNOGLOBULINA UMANA NORMALE
KEDRION S.P.A
2020 Phase 3 EUCTR2020-001496-32-IT Hungary;Italy;Portugal;Slovakia;
IV treatment with IGSC,
Baxalta now part of Shire
2010 Phase 3 NCT01175213 United States;
IVIG
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
IVIG-PEG
Grifols Therapeutics LLC
2020 Phase 3 NCT04561115 United States;
Ibuprofen
IRCCS San Raffaele
2015 Phase 2 NCT03055247 Italy;
Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy;
IgG Next Generation
Biotest AG
2017 Phase 3 EUCTR2015-003652-52-GB Germany;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-ES Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-DE Germany;Russian Federation;Spain;United Kingdom;United States;
IgG Next Generation (BT595)
Biotest
2016 Phase 3 NCT02810444 Germany;Hungary;Russian Federation;Spain;United States;
IgHy10
University Hospital, Lille
2016 Phase 4 NCT02881437 France;
IgNextGen
CSL Limited
2007 Phase 3 NCT00391131 Australia;New Zealand;
IgPro10
CSL Behring KK
- Phase 3 EUCTR2016-001631-12-Outside-EU/EEA Japan;
IgPro20
CSL Behring
2017 Phase 4 NCT03033745 Canada;United States;
2008 Phase 3 NCT00751621 France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
2008 Phase 3 NCT00719680 United States;
2008 Phase 3 EUCTR2006-006745-13-PL France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
CSL Behring AG
2008 Phase 3 EUCTR2008-000830-30-GB France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
2008 Phase 3 EUCTR2008-000830-30-FR France;Germany;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000830-30-SE France;Germany;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000830-30-ES France;Germany;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000830-30-DE France;Germany;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-GB France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-FR France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-ES France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-SE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-DE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
- - EUCTR2014-003607-30-Outside-EU/EEA United States;
CSL Behring AG (casa madre)
2007 - EUCTR2006-006745-13-IT France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
CSL Behring LLC
- Phase 4 EUCTR2016-003799-33-Outside-EU/EEA Canada;United States;
Immune Globulin Infusion (Human),
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01485796 United States;
Immune Globulin Intravenous (Human)
Grifols Therapeutics Inc.
2006 Phase 2 NCT00389324 Canada;United States;
Immune Globulin Intravenous (Human) Liquid, IVIG-SN™
Green Cross Corporation
2011 Phase 3 NCT01406470 Canada;United States;
Immune Globulin Intravenous (Human),
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01412385 Austria;Germany;Hungary;Sweden;United Kingdom;
2007 Phase 2/Phase 3 NCT00546871 United States;
2002 Phase 3 NCT00157079 United States;
Immune Globulin Intravenous (Human), Solution
Baxalta now part of Shire
2013 Phase 2/Phase 3 NCT01218438 Canada;United States;
Immune Globulin Intravenous (Human), TVR (Triple Virally Reduced) Solution
Baxalta now part of Shire
2002 Phase 2 NCT00161993 Finland;Sweden;
Immune Globulin Intravenous (IGIV)
Baxalta now part of Shire
2020 Phase 3 NCT04346108 Japan;
Immune Globulin Intravenous [Human], Caprylate/Chromatography Purified
Grifols Therapeutics Inc.
2002 Phase 3 NCT00220766 Canada;United States;
Immune Globulin Subcutaneos,
Baxter Innovations GmbH
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Immune Globulin Subcutaneous (Human) (SCIG)
CSL Behring
2010 Phase 3 NCT01199705 Japan;
Immune Globulin Subcutaneous (Human),
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01412385 Austria;Germany;Hungary;Sweden;United Kingdom;
Immune Globulin Subcutaneous (Human), , Caprylate/Chromatography Purified
Grifols Therapeutics Inc.
2017 Phase 3 EUCTR2015-003290-15-HU Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-GB Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-FR Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-ES Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-DE Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-CZ Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
- Phase 3 EUCTR2015-003290-15-PL Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
Immune Globulin Subcutaneous (Human), Caprylate/Chromatography Purified (IGSC )
Grifols Therapeutics Inc.
2017 Phase 3 EUCTR2015-003290-15-HU Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-GB Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-FR Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-ES Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-DE Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-CZ Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
- Phase 3 EUCTR2015-003290-15-PL Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
Immune Globulin Subcutaneous (Human), Solution
Baxalta now part of Shire
2013 Phase 2/Phase 3 NCT01218438 Canada;United States;
Immune Globulin Subcutaneous,
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Immune Globulin Subcutaneous, Solution (IGSC, )
Baxalta now part of Shire
2020 Phase 3 NCT04346108 Japan;
Immune globulin subcutaneous (Human)
CSL Behring
2011 Phase 3 NCT01461018 Japan;
2011 Phase 3 NCT01458171 Japan;
Immune globulin subcutaneous (human)
CSL Behring AG
2008 Phase 4 EUCTR2006-006522-25-GR Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-GB Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-ES Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-DE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-BE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
Immunglobulin (human)
CSL Behring AG
2007 - EUCTR2006-006522-25-IT Belgium;Germany;Greece;Italy;Spain;United Kingdom;
Immunoglobulin G
OCTAPHARMA AG
2010 - EUCTR2009-011434-10-DE Germany;
- - EUCTR2009-011434-10-Outside-EU/EEA United States;
Immunoglobulin G (Ig NextGen )
CSL Limited
2008 Phase 3 NCT00680446 Australia;New Zealand;
Immunoglobulin intravenous (human)
CSL Behring KK
- Phase 3 EUCTR2016-001631-12-Outside-EU/EEA Japan;
Immunoglobulins Intravenous (Human)
CSL Behring
2005 Phase 3 NCT00322556 United States;
2004 Phase 3 NCT00168025 -
2004 Phase 3 NCT00168012 -
Immunoglobulins, normal human
CSL Behring AG (casa madre)
2007 - EUCTR2006-006745-13-IT France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
Immunological diagnosis tests
University Hospital, Lille
2015 - NCT02972281 France;
Immunosuppression Only Conditioning
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
Immunosuppression Only Conditioning -Closed with amendment L
National Cancer Institute (NCI)
2015 Phase 2 NCT02579967 United States;
In vitro-treated peripheral blood stem cell transplantation
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
Increlex
National Institute of Allergy and Infectious Diseases (NIAID)
2007 Phase 1/Phase 2 NCT00490100 United States;
Infliximab
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Phase 1/Phase 2 NCT00325078 United States;
Infusion of autologous EFS-ADA LV CD34+ (OTL-101)
Orchard Therapeutics
2013 Phase 1/Phase 2 NCT01852071 United States;
Infusion of autologous EFS-ADA LV CD34+ cells
Great Ormond Street Hospital for Children NHS Foundation Trust
2012 Phase 1/Phase 2 NCT01380990 United Kingdom;
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1/Phase 2 NCT03765632 United Kingdom;
Orchard Therapeutics
2016 Phase 1/Phase 2 NCT02999984 United States;
Interferon-gamma
National Institute of Allergy and Infectious Diseases (NIAID)
1992 Phase 4 NCT00001317 United States;
Intratect
Biotest AG
2010 - EUCTR2010-019249-25-HU Germany;Hungary;
2010 - EUCTR2010-019249-25-DE Germany;Hungary;
2005 - EUCTR2004-004465-15-HU Germany;Hungary;
2005 - EUCTR2004-004465-15-DE Germany;Hungary;
Intravenous immunoglobulin infusion
Sanquin
2013 Phase 3 NCT01985373 Netherlands;
Intravenous infusion of transduced cells
Great Ormond Street Hospital for Children NHS Foundation Trust
2003 Phase 1/Phase 2 NCT01279720 United Kingdom;
Isolex 300i Magnetic Cell Selector
National Institute of Allergy and Infectious Diseases (NIAID)
1995 Phase 1 NCT00001476 United States;
Itraconazole
National Institute of Allergy and Infectious Diseases (NIAID)
1991 Phase 2 NCT00001280 United States;
Jardiance
Cliniques universitaires Saint-Luc
2019 Phase 4 EUCTR2018-004191-35-BE Belgium;
KIOVIG
Baxalta now part of Shire
2017 Phase 4 NCT03116347 Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
KIOVIG 100 mg/ml solution for infusion
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Baxter Innovations GmbH
2012 - EUCTR2012-000481-38-GB Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
KIg10
KEDRION S.P.A
2021 Phase 3 EUCTR2020-001496-32-PT Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-SK Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-IT Hungary;Italy;Portugal;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-HU Hungary;Italy;Portugal;Russian Federation;Slovakia;
KLH
National Institute of Allergy and Infectious Diseases (NIAID)
1999 Phase 2 NCT00001145 United States;
KVD824
KalVista Pharmaceuticals, Ltd.
2021 Phase 2 NCT05055258 Australia;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;Puerto Rico;United Kingdom;United States;
KVD824 300 mg Compresse a rilascio modificato
KalVista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD824 300 mg Modified Release Tablets
Kalvista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-HU Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-DE Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD824 hydrochloride
KalVista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
Kalvista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-HU Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-DE Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD900
KalVista Pharmaceuticals, Ltd.
2022 Phase 3 NCT05259917 -
2019 Phase 2 NCT04208412 Austria;Czechia;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
KVD900 100 mg Film Coated Tablet
KalVista Pharmaceuticals Ltd
2019 Phase 2 EUCTR2018-004489-32-IT Austria;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-GB Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States;
KalVista Pharmaceuticals Ltd.
2019 Phase 2 EUCTR2018-004489-32-PL Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-NL Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-HU Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;
2019 Phase 2 EUCTR2018-004489-32-DE Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-AT Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
Kedrion IVIG
Kedrion S.p.A.
2021 Phase 3 NCT04944979 Hungary;Italy;Slovakia;
2019 Phase 3 NCT03961009 Canada;United States;
2012 Phase 3 NCT01581593 Canada;United States;
Kineret
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2015 Early Phase 1 NCT04136028 Russian Federation;
L-Arginin-hydrochlorid-einmolar Fresenius
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
L-fucose
Orpha Labs
2012 Phase 1/Phase 2 NCT03354533 -
LADICell
Rocket Pharmaceuticals, Inc.
2020 Phase 1;Phase 2 EUCTR2020-000517-33-GB Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2018-002680-26-ES Spain;
LDT
Progenity, Inc.
2015 - NCT02787486 United States;
LFB-IgSC
LFB Biotechnologies
2014 - EUCTR2013-000620-34-GB France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-IT France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-HU France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-DE France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
Lemtrada
Karolinska Universitetssjukhuset
2018 Phase 2 EUCTR2018-001489-41-SE Sweden;United States;
Leniolisib
NOVARTIS PHARMA SERVICES AG
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IT Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Novartis Pharma Services AG
2021 Phase 2;Phase 3 EUCTR2016-000468-41-FR Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2016-000468-41-GB Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-NL Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-CZ Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Pharming Technologies B.V.
- Phase 2;Phase 3 EUCTR2016-000468-41-DE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Lentiviral G1XCGD Gene Therapy
University of California, Los Angeles
2015 Phase 1/Phase 2 NCT02234934 United States;
Lentiviral vector transduced CD34+ cells
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1 NCT03601286 United Kingdom;
MABTHERA - 2 FIALE 100 MG 10 ML
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
MBM-01
Matrix Biomed, Inc.
2021 Phase 2 NCT04887311 United States;
MCTLs
Catherine Bollard
2014 Phase 1 NCT02510404 United States;
MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
MYELOSTIM
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO + SIRINGA PRERIEMPITA SOLVENTE 1 ML
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
MabThera
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Mavorixafor
X4 PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001153-10-IT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
X4 Pharmaceuticals
2020 Phase 1 NCT04154488 United States;
2019 Phase 3 NCT03995108 Australia;Austria;Denmark;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United States;
X4 Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-001153-10-PL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-NL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-HU Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-GB Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-FR Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-ES Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-DE Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-AT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001153-10-DK Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d
Epicentre
2001 Phase 3 NCT00330148 Uganda;
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d
Epicentre
2001 Phase 3 NCT00330148 Uganda;
Melphalan
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Metformin
NHS Tayside
2016 Phase 4 NCT02733679 United Kingdom;
Methotrexate
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Methylprednisolone
Fairview University Medical Center
2000 - NCT00006054 United States;
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Methylprednisolone or Prednisolone
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Miltenyi CliniMACS
St. Jude Children's Research Hospital
2004 Phase 1 NCT00152100 United States;
Miltenyi CliniMACS selection system
St. Jude Children's Research Hospital
2005 Phase 1 NCT00160355 United States;
Mozobil
IRCCS San Raffaele
2015 Phase 2 NCT03055247 Italy;
Mozobil 20mg/mL vial (injectable solution for subcutaneous use)
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Mozobil 20mg/mL vial (injectable solution, subcutaneous use)
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Mozobil,
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Mycophenolate mofetil
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Mycophenolate mofetil (MMF)
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Myeloablative Conditioning-Closed with amendment L
National Cancer Institute (NCI)
2015 Phase 2 NCT02579967 United States;
Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Myelostim
IRCCS San Raffaele
2015 Phase 2 NCT03055247 Italy;
N-Acetyl-L-Leucine
IntraBio Ltd.
2019 Phase 2 EUCTR2018-004407-39-GB Germany;United Kingdom;United States;
NDV-3A
National Institute of Allergy and Infectious Diseases (NIAID)
2016 Phase 2 NCT02996448 United States;
Nanogam 100 mg/ml
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
Nanogam® 50 mg/ml
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
Neopterin
Institut de Recherche pour le Developpement
2017 - NCT03112655 Congo, The Democratic Republic of the;
NewGam
OCTAPHARMA AG
2010 - EUCTR2009-011434-10-DE Germany;
- - EUCTR2009-011434-10-Outside-EU/EEA United States;
Octapharma
2011 Phase 3 NCT01313507 United States;
2010 Phase 3 NCT01012323 United States;
Newnorm
Octapharma
2021 Phase 3 NCT04640142 Germany;Poland;Slovakia;Ukraine;United States;
Octapharma Pharmazeutika Prod.Ges.m.b.H
2021 Phase 1;Phase 3 EUCTR2020-004734-37-DE Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
- Phase 1;Phase 3 EUCTR2020-004734-37-SK Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
- Phase 1;Phase 3 EUCTR2020-004734-37-PL Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
Nicotinamide ribonucleoside
University Hospital, Akershus
2019 Phase 2 NCT04870866 Norway;
Nifurtimox
Drugs for Neglected Diseases
2012 Phase 2/Phase 3 NCT01685827 Central African Republic;Congo;Congo, The Democratic Republic of the;
2004 Phase 3 NCT00146627 Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;
Universidad Autónoma de Bucaramanga
2015 Phase 2/Phase 3 NCT02369978 Colombia;
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
Epicentre
2001 Phase 3 NCT00330148 Uganda;
Nifurtimox-Eflronithine Combination Treatment (NECT)
Drugs for Neglected Diseases
2009 Phase 4 NCT00906880 Congo;
None
KalVista Pharmaceuticals Ltd
2019 Phase 2 EUCTR2018-004489-32-GB Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States;
KalVista Pharmaceuticals Ltd.
2019 Phase 2 EUCTR2018-004489-32-PL Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-NL Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-HU Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;
2019 Phase 2 EUCTR2018-004489-32-DE Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-AT Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00358657 United States;
1997 Phase 1 NCT00008450 United States;
Normal human immunoglobulin G
CSL Behring AG
2008 - EUCTR2008-000830-30-SE France;Germany;Spain;Sweden;United Kingdom;
Norovirus -specific T-cell (NST) therapy
Children's National Research Institute
2020 Phase 1 NCT04691622 United States;
Noxafil 40 mg/ml oral solution
Radboud University Nijmegen Medical Centre
2009 - EUCTR2008-004518-28-GB Netherlands;United Kingdom;
2008 - EUCTR2008-004518-28-NL Netherlands;United Kingdom;
NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
OCTA-C1-INH
Octapharma Pharmazeutika Produktionsges.m.b.H.
2020 Phase 2 EUCTR2019-001693-28-DE Belarus;Germany;Russian Federation;Ukraine;
OCTAGAM 50 mg/ml oldatos infúzió
OCTAPHARMA AG
2012 - EUCTR2012-000792-16-HU Czech Republic;Germany;Hungary;
ORENCIA® 125 mg solution for injection in pre-filled syringe
Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
2016 Phase 2 EUCTR2015-002491-24-DE Germany;
OTL-101
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
Orchard Therapeutics
2019 Phase 2/Phase 3 NCT04140539 United States;
OTL-103 Dispersion for Infusion
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Octagam
OCTAPHARMA AG
2012 - EUCTR2012-000792-16-DE Czech Republic;Germany;Hungary;
Octapharma
2009 Phase 3 NCT00811174 Austria;
Octapharma AG
2010 Phase 3 EUCTR2007-002611-27-GB France;Germany;United Kingdom;
2010 - EUCTR2007-002611-27-FR France;United Kingdom;
2008 - EUCTR2007-002611-27-DE France;Germany;United Kingdom;
Octanorm
Octapharma
2017 Phase 3 NCT03988426 Russian Federation;
2016 Phase 3 NCT03907241 Canada;United States;
2016 Phase 3 NCT02627300 Canada;United States;
2014 Phase 3 NCT01888484 Canada;Czech Republic;Czechia;Hungary;Poland;Russian Federation;Slovakia;United States;
Octapharma Pharmazeutika Prod.Ges.m.b.H
2017 Phase 1;Phase 3 EUCTR2013-003877-87-SK Canada;Czech Republic;Hungary;Poland;Russian Federation;Slovakia;United States;
2015 Phase 3 EUCTR2013-003877-87-PL Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
2014 Phase 3 EUCTR2013-003877-87-HU Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
2014 Phase 1;Phase 3 EUCTR2013-003877-87-CZ Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
Omalizumab (Xolair)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 1 NCT00260702 United States;
Other hematological Agents
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Ovastat 1000 (Treosulfan injection)
medac Gesellschaft fuer klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-AT Austria;Czech Republic;Germany;Italy;Poland;
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-DE Austria;Czech Republic;Germany;Italy;Poland;
medac GmbH
2015 - EUCTR2013-005508-33-IT Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-PL Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 1000 mg, powder for solution for infusion
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-CZ Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 5000 (Treosulfan injection)
medac Gesellschaft fuer klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-AT Austria;Czech Republic;Germany;Italy;Poland;
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-DE Austria;Czech Republic;Germany;Italy;Poland;
medac GmbH
2015 - EUCTR2013-005508-33-IT Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-PL Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 5000 mg, powder for solution for infusion
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-CZ Austria;Czech Republic;Germany;Italy;Poland;
PEG-ADA ERT
Orchard Therapeutics
2016 Phase 1/Phase 2 NCT02999984 United States;
2013 Phase 1/Phase 2 NCT01852071 United States;
PEG-interleukin-2
Mount Sinai School of Medicine
1997 - NCT00004695 -
PHA-022121
Pharvaris Netherlands B.V.
2022 Phase 2 NCT05047185 Canada;United Kingdom;United States;
2021 Phase 2 NCT04618211 Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Pharvaris Netherlands BV
2022 Phase 2 EUCTR2021-000227-13-PL Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2022 Phase 2 EUCTR2021-000227-13-BG Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-PL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-NL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-HU Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
2021 Phase 2 EUCTR2020-003445-11-DE Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-BG Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2020-003445-11-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
- Phase 2 EUCTR2020-003445-11-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PHVS416
Pharvaris Netherlands BV
2022 Phase 2 EUCTR2021-000227-13-PL Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2022 Phase 2 EUCTR2021-000227-13-BG Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-PL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-NL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-HU Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
2021 Phase 2 EUCTR2020-003445-11-DE Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-BG Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2020-003445-11-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
- Phase 2 EUCTR2020-003445-11-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PID
Children's Hospital of Chongqing Medical University
2020 Phase 0 ChiCTR2000032139 China;
PNEUMO 23
Inserm
2009 - EUCTR2007-003235-23-FR France;
PREVENAR
Inserm
2009 - EUCTR2007-003235-23-FR France;
PROLEUKIN® S
Universitätsklinikum Freiburg
2016 Phase 2 EUCTR2015-003369-27-DE Germany;
PSRS11.EFS.IL2RG.pre* retroviral vector transduce
Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
2010 Phase 1;Phase 2 EUCTR2007-000684-16-GB United Kingdom;
PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells
Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
2010 Phase 1;Phase 2 EUCTR2007-000684-16-GB United Kingdom;
PTH 1-34
National Institute of Dental and Craniofacial Research (NIDCR)
2006 Phase 3 NCT00395538 Austria;Italy;United States;
Palifermin
National Institute of Allergy and Infectious Diseases (NIAID)
2012 Phase 1/Phase 2 NCT03315078 United States;
2012 Phase 1/Phase 2 NCT01306019 United States;
Pantoprazolo 20 mg gastro-resistant tablets
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Peg-Ada
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1/Phase 2 NCT03765632 United Kingdom;
2012 Phase 1/Phase 2 NCT01380990 United Kingdom;
Pentamidine
Immtech Pharmaceuticals, Inc
2003 Phase 2 NCT00803933 Congo;
Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Peripheral blood stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Peripheral blood stem cells
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02629120 United States;
Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Early Phase 1 NCT00394316 United States;
Pioglitazone
Children's Hospital of Fudan University
2017 Phase 1/Phase 2 NCT03080480 China;
NHS Tayside
2016 Phase 4 NCT02733679 United Kingdom;
Plerixafor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT03547830 Russian Federation;
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 2/Phase 3 NCT02231879 United States;
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Plerixafor for Conditioning before HSCT.
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2016 Phase 2 NCT03019809 Russian Federation;
PnCJ PPS
Institut National de la Santé Et de la Recherche Médicale, France
2009 Phase 2 NCT01489618 France;
Pneumovax® (pneumococcal polysaccharide vaccine)
Sheba Medical Center
2010 - NCT01075438 Israel;
Polyclonal IgG
Federico II University
2010 - NCT03534479 Italy;
Posaconazole (PSZ)
Radboud University
2009 Phase 2 NCT00799071 Netherlands;United Kingdom;
Prednisone
Fairview University Medical Center
2000 - NCT00006054 United States;
Prevenar
Great Ormond Street Hospital
2005 Phase 4 EUCTR2005-004122-70-GB United Kingdom;
Prevenar® (7-valent pneumococcal conjugate vaccine)
Sheba Medical Center
2010 - NCT01075438 Israel;
Privigen
CSL Behring KK
- Phase 3 EUCTR2016-001631-12-Outside-EU/EEA Japan;
Privigen®
CSL Behring AG
- - EUCTR2014-003772-23-Outside-EU/EEA United States;
Progynova 21 mite
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Promacta
Weill Medical College of Cornell University
2009 Phase 2 NCT00909363 United States;
Prometic's Immune Globulin Intravenous
Prometic Biotherapeutics, Inc.
2016 Phase 3 NCT02269163 United States;
Purified Vero Cell Vaccine)
Chulalongkorn University
2015 Phase 4 NCT02490956 Thailand;
Pyrimethamine
National Institute of Allergy and Infectious Diseases (NIAID)
2003 Phase 1 NCT00065390 United States;
R-hIL-18BP
AB2 Bio Ltd.
2019 Phase 3 EUCTR2018-003297-27-DE Canada;Germany;United States;
- Phase 3 EUCTR2018-003199-10-DE Canada;Germany;United States;
RAG1 LV CD34+ cells
Leiden University Medical Center
2020 Phase 1;Phase 2 EUCTR2019-002343-14-NL Netherlands;
RI-002
ADMA Biologics, Inc.
2014 Phase 3 NCT01814800 United States;
RP-L201
Rocket Pharmaceuticals Inc.
2019 Phase 1/Phase 2 NCT03812263 Spain;United Kingdom;United States;
2019 Phase 1 NCT03825783 Spain;
Rocket Pharmaceuticals, Inc.
2020 Phase 1;Phase 2 EUCTR2020-000517-33-GB Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2018-002680-26-ES Spain;
Rabbit anti-thymocyte globulin
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Ranitidine
National Institute of Allergy and Infectious Diseases (NIAID)
2007 Phase 2 NCT00527878 United States;
Recombinant Human Hyaluronidase (rHuPH20)
Baxter Innovations GmbH
2012 - EUCTR2012-000481-38-GB Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
Recombinant human hyaluronidase
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01485796 United States;
Nishizawa Atsushi
2022 Phase 3 JPRN-jRCT2031210457 Japan;
Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Baxalta now part of Shire
2008 Phase 3 NCT00814320 Canada;United States;
Recombinant human hyaluronidase + immune globulin intravenous
Baxalta now part of Shire
2006 Phase 1/Phase 2 NCT00782106 United States;
Reduced Intensity Conditioning
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
2015 Phase 2 NCT02579967 United States;
Reduced Intensity Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Reduced Toxicity Ablative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Retroviral SF71-gp91phox transduced CD34+ cells
Johann Wolfgang Goethe University Hospitals
2004 Phase 1/Phase 2 NCT00564759 Germany;
Retrovirus-mediated gene transfer
David Williams
2011 Phase 1/Phase 2 NCT01410825 United States;
RhuCD40L
National Institute of Allergy and Infectious Diseases (NIAID)
1999 Phase 2 NCT00001145 United States;
Rifaximin
Oslo University Hospital
2013 Phase 4 NCT01946906 Norway;
Rimiducid
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
Rituximab
National Center for Child Heath and Development
2018 Phase 1,2 JPRN-UMIN000030806 Japan;
Rituximab (RTX) and Azathioprine (AZA)
Medical College of Wisconsin
2016 Phase 2 NCT02789397 -
Rivogenlecleucel
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
Romiplostim
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT04371939 Russian Federation;
2012 - NCT04350164 Russian Federation;
SC treatment with IGSC, with rHuPH20 followed by IV/IGSC, only (safety)
Baxalta now part of Shire
2010 Phase 3 NCT01175213 United States;
SC treatment with IGSC, with rHuPH20 followed by SC/IGSC, only (safety)
Baxalta now part of Shire
2010 Phase 3 NCT01175213 United States;
SCID screening
Nantes University Hospital
2014 - NCT02244450 France;
SCYX-7158
Drugs for Neglected Diseases
2012 Phase 1 NCT01533961 France;
STA-5326
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 1 NCT00263237 United States;
STRIMVELIS
Orchard Therapeutics
2018 - NCT03232203 Italy;
SUBCUVIA
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States;
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00358657 United States;
Imai Kohsuke
2022 Phase 2 JPRN-jRCT2031210309 Japan;
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
2019 Early Phase 1 NCT03910452 United States;
2015 Phase 1/Phase 2 NCT02629120 United States;
2014 Phase 1/Phase 2 NCT02282904 United States;
University of California, San Francisco
2014 Phase 2 NCT02177760 United States;
Sodium chloride
AB2 Bio Ltd.
2017 Phase 3 NCT03113760 Canada;Germany;United States;
Somatic gene-therapy by X-CGD
Johann Wolfgang Goethe-University
2013 Phase 1;Phase 2 EUCTR2012-001725-26-DE Germany;
Somatotropin
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
Johann Wolfgang Goethe University Hospitals
2010 Phase 4 NCT01052623 Germany;
Stelara (ustekinumab)
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02199496 United States;
Stem Cell Infusion
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
2007 Phase 2/Phase 3 NCT00455312 United States;
Stem cell infusion
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Stem cell transplant
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
St. Jude Children's Research Hospital
2004 Phase 1 NCT00152100 United States;
Strimvelis
Orchard Therapeutics (Europe) Ltd
2017 Phase 4 EUCTR2017-001731-39-IT Italy;Switzerland;Turkey;
Subgam
Bio Products Laboratory
2015 Phase 3 NCT01884311 United States;
Suspension of autologous CD34+cells transduced with the G1XCGD viral vector
GENETHON
2013 - EUCTR2012-000242-35-DE France;Germany;Switzerland;United Kingdom;
Genethon
2013 Phase 1;Phase 2 EUCTR2012-000242-35-GB France;Germany;Switzerland;United Kingdom;
T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 3 NCT00023192 United States;
TAK-771
Takeda
2022 Phase 3 NCT05150340 Japan;
TBX-1400
Taiga Biotechnologies, Inc.
2021 Phase 1 NCT02860559 Israel;
TCR alfa beta T cell depletion
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2012 Phase 2/Phase 3 NCT02327351 Russian Federation;
TYF-IL-2Rg gene-modified autologous stem cells
Shenzhen Geno-Immune Medical Institute
2017 Phase 1/Phase 2 NCT03217617 China;
Tabelecleucel
Atara Biotherapeutics
2021 Phase 2 NCT04554914 Austria;Belgium;France;Italy;Spain;United Kingdom;United States;
2016 - NCT02822495 United States;
Tablets Fexinidazole
Drugs for Neglected Diseases
2011 Phase 1 NCT01483170 France;
Tacrolimus
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00358657 United States;
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Tacrolimus (Tacro)
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Tadekinig alfa
AB2 Bio Ltd.
2018 Phase 3 NCT03512314 Canada;Germany;United States;
2017 Phase 3 NCT03113760 Canada;Germany;United States;
Thalidomide
Kawai Toshinao
2017 Phase 2-3 JPRN-jRCT2031200236 Japan;
National Center for Child Heath and Development
2017 - JPRN-UMIN000029324 Japan;
2012 - JPRN-UMIN000009370 Japan;
Therapeutic allogeneic lymphocytes
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
There is no recommended INN
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
Thiotepa
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
Thiotepa--escalated dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Thiotepa--single daily dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Thymafalsin
Erasmus MC
2022 Phase 2 EUCTR2021-003327-15-NL Netherlands;
Thymus Tissue for Transplantation
M. Louise Markert
2002 Phase 1 NCT00579709 United States;
Thymus/Parathyroid Transplantation
M. Louise Markert
2005 Phase 1 NCT00566488 United States;
To be confirmed
Kalvista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-HU Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-DE Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
Total Body Irradiation
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
Total lymphoid irradiation
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Traditional treatment of CGD and TB
Children's Hospital of Fudan University
2019 Phase 2/Phase 3 NCT03984890 China;
Transduced Lymphocytes
National Human Genome Research Institute (NHGRI)
1990 - NCT00001255 United States;
Transplant Conditioning with Mobilization Only
University of California, San Francisco
2010 Phase 2 NCT01182675 United States;
Transplant Conditioning with Mobilization and Alemtuzumab
University of California, San Francisco
2010 Phase 2 NCT01182675 United States;
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Washington University School of Medicine
2013 Phase 2 NCT01821781 United States;
Treosulfan
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2020 Phase 2 NCT04400045 Russian Federation;
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
medac GmbH
2015 Phase 2 NCT02349906 Austria;Czech Republic;Czechia;Germany;Italy;Poland;
Triheptanoin
The University of Queensland
2022 Phase 2 NCT04513002 Australia;
Umbilical cord blood transplantation
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Unrelated BM with T cell depletion
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Unrelated PBSC with T cell depletion
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Unrelated cord blood
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Ustekinumab
National Institute of Allergy and Infectious Diseases (NIAID)
2018 Phase 1/Phase 2 NCT03366142 United States;
VM106
Helixmith Co., Ltd.
2007 Phase 1/Phase 2 NCT00778882 Korea, Republic of;
Valacyclovir
National Institute of Allergy and Infectious Diseases (NIAID)
2000 Phase 3 NCT00031486 Canada;Sweden;United Kingdom;United States;
Verorab® (PVRV
Chulalongkorn University
2015 Phase 4 NCT02490956 Thailand;
Vigantol
Karolinska University Hospital
2010 Phase 1/Phase 2 NCT01131858 Sweden;
Vinblastine, vincristine, prednisone, daunorubicin
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Vitamin B3
Radboud University
2019 Phase 2 NCT03962114 Netherlands;
Vitamin D3
Children's Hospital of Fudan University
2019 Phase 2/Phase 3 NCT03984890 China;
Vivaglobin
CSL Behring
2007 Phase 4 NCT00520494 Belgium;Canada;Germany;Italy;Spain;
CSL Behring AG
2008 Phase 4 EUCTR2006-006522-25-GR Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-GB Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-ES Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-IT Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-DE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-BE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
X4P-001
X4 PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001153-10-IT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
X4 Pharmaceuticals
2016 Phase 2 NCT03005327 Australia;United States;
X4 Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-001153-10-PL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-NL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-HU Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-GB Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-FR Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-ES Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-DE Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-AT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001153-10-DK Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
XELJANZ (tofacitinib)
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT05104723 United States;
Xifaxan
Oslo University hospital
2013 - EUCTR2013-000883-27-NO Norway;
Zadaxin
Erasmus MC
2022 Phase 2 EUCTR2021-003327-15-NL Netherlands;
Zarzio
Sandoz GmbH
2012 Phase 4 EUCTR2011-001118-32-SE Germany;Sweden;
Zoledronate
Department of Pediatrics, Tokyo Medical and Dental University
2014 - JPRN-UMIN000013102 Japan;
Ottawa Hospital Research Institute
2018 Phase 4 NCT03677557 Canada;
2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID
IntraBio Ltd
2020 Phase 2 EUCTR2018-004407-39-DE Germany;Spain;United Kingdom;United States;
36-482-Hyaluronoglucosaminidase PH20 (rHuPH20)
Baxter Innovations GmbH
2012 - EUCTR2012-000481-38-GB Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
A10BK03
Cliniques universitaires Saint-Luc
2019 Phase 4 EUCTR2018-004191-35-BE Belgium;
ADA PBSC
National Human Genome Research Institute (NHGRI)
1990 - NCT00001255 United States;
ADA Umbilical Cord Blood Cells
National Human Genome Research Institute (NHGRI)
1990 - NCT00001255 United States;
ADA gene transfer
Donald B. Kohn, M.D.
2008 Phase 2 NCT00794508 United States;
AProArt
University of California, San Francisco
2018 Phase 1/Phase 2 NCT03538899 United States;
AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR
GENETHON
2013 - EUCTR2012-000242-35-DE France;Germany;Switzerland;United Kingdom;
Genethon
2013 Phase 1;Phase 2 EUCTR2012-000242-35-GB France;Germany;Switzerland;United Kingdom;
Abatacept
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT04925375 United States;
Emory University
2014 Phase 1 NCT01917708 United States;
Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
2016 Phase 2 EUCTR2015-002491-24-DE Germany;
Acoziborole
Drugs for Neglected Diseases
2021 Phase 2/Phase 3 NCT05256017 Congo, The Democratic Republic of the;Guinea;
Acoziborole (SCYX-7158)
Drugs for Neglected Diseases
2016 Phase 2/Phase 3 NCT03087955 Congo, The Democratic Republic of the;Guinea;
Adagen
Leadiant Biosciences, Inc.
2014 Phase 3 NCT01420627 United States;
Administration of drug (Interferon-gamma 1-b) subcutaneously
University of Colorado, Denver
2016 Phase 1 NCT02609932 United States;
Adverse Reactions of Gammagard subcutaneously at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subcutaneously at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subcutaneously at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subdermally at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subdermally at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Adverse Reactions of Gammagard subdermally at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Alefacept
Emory University
2010 - NCT01319851 United States;
Alemtuzumab
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2012 - NCT01652092 United States;
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2019 Early Phase 1 NCT03910452 United States;
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Alentuzumab (Campath)
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02629120 United States;
Allo BMT
National Cancer Institute (NCI)
2015 Phase 2 NCT02579967 United States;
Allogeneic Bone Marrow Transplantation
Fairview University Medical Center
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00358657 United States;
1997 Phase 1 NCT00008450 United States;
Allogeneic HSC
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
Allogeneic HSCT
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Allogeneic bone marrow transplantation
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2005 Phase 1 NCT00295971 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Allogeneic hematopoietic stem cell transplantation
Fairview University Medical Center
2000 - NCT00006056 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2005 Phase 1 NCT00295971 United States;
Allogeneic peripheral blood stem cell
National Institute of Allergy and Infectious Diseases (NIAID)
2019 Early Phase 1 NCT03910452 United States;
Anti-CD45
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2000 Phase 2/Phase 3 NCT00176878 United States;
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Anti-thymocyte globulin (rabbit)
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
Antithymocyte globulin
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
Argininhydrochlorid
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Asceniv™
ADMA Biologics, Inc.
2022 Phase 4 NCT05070455 -
Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
2012 Phase 1;Phase 2 EUCTR2010-024253-36-GB United Kingdom;
Autologous CD34+ cell transduced with G2SCID vector
David Williams
2018 Phase 1/Phase 2 NCT03311503 United Kingdom;United States;
Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy
GENETHON
- Phase 1;Phase 2 EUCTR2009-011152-22-FR France;
Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Orchard Therapeutics
2019 - NCT04049084 United Kingdom;United States;
B-Lymphocyte Stimulator (BLyS)
National Cancer Institute (NCI)
2001 Phase 1 NCT00024934 United States;
BMS-188667
Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
2016 Phase 2 EUCTR2015-002491-24-DE Germany;
BPX-501 T cells
Bellicum Pharmaceuticals
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
BT090
Biotest AG
2010 - EUCTR2010-019249-25-HU Germany;Hungary;
2010 - EUCTR2010-019249-25-DE Germany;Hungary;
BT524
Biotest AG
2013 Phase 1;Phase 2 EUCTR2011-004154-25-IT Egypt;Germany;Italy;Lebanon;
BT595
Biotest AG
2017 Phase 3 EUCTR2015-003652-52-GB Germany;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-ES Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-DE Germany;Russian Federation;Spain;United Kingdom;United States;
BT681
Biotest AG
2005 - EUCTR2004-004465-15-HU Germany;Hungary;
2005 - EUCTR2004-004465-15-DE Germany;Hungary;
BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
Baclofen
Johns Hopkins University
2007 Early Phase 1 NCT00640003 United States;
Bacteriophage
National Institute of Allergy and Infectious Diseases (NIAID)
1999 Phase 2 NCT00001145 United States;
Benznidazole
Population Health Research Institute
2004 Phase 3 NCT00123916 Argentina;Bolivia;Brazil;Canada;Colombia;El Salvador;
Universidad Autónoma de Bucaramanga
2015 Phase 2/Phase 3 NCT02369978 Colombia;
Biological sampling
Imagine Institute
2015 - NCT02909244 France;
Bivigam
ADMA Biologics, Inc.
2016 - NCT03037359 United States;
Blood Draw
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Blood Sample
Koneti Rao
2008 Phase 1/Phase 2 NCT00605657 United States;
Busilvex
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
medac Gesellschaft fuer klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-AT Austria;Czech Republic;Germany;Italy;Poland;
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-DE Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-CZ Austria;Czech Republic;Germany;Italy;Poland;
medac GmbH
2015 Phase 2 NCT02349906 Austria;Czech Republic;Czechia;Germany;Italy;Poland;
2015 - EUCTR2013-005508-33-IT Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-PL Austria;Czech Republic;Germany;Italy;Poland;
Busulfan
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1/Phase 2 NCT03765632 United Kingdom;
2012 Phase 1/Phase 2 NCT01380990 United Kingdom;
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
2000 Phase 2/Phase 3 NCT00176878 United States;
Michael Pulsipher, MD
2018 Phase 2 NCT03619551 United States;
National Center for Child Health and Development
2017 - JPRN-UMIN000030647 Japan;
2016 - JPRN-UMIN000022688 Japan;
National Center for Child Heath and Development
2018 Phase 1,2 JPRN-UMIN000030806 Japan;
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
2019 Early Phase 1 NCT03910452 United States;
2014 Phase 1/Phase 2 NCT02282904 United States;
2012 Phase 1/Phase 2 NCT03315078 United States;
2012 Phase 1/Phase 2 NCT01306019 United States;
Orchard Therapeutics
2016 Phase 1/Phase 2 NCT02999984 United States;
2013 Phase 1/Phase 2 NCT01852071 United States;
Sakaguchi Hirotoshi
2018 Phase 2 JPRN-jRCTs031180398 Japan;None (Japan only);
Seoul National University Hospital
2011 Phase 1/Phase 2 NCT01338675 Korea, Republic of;
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
2016 Phase 1/Phase 2 NCT01512888 United States;
University of California, San Francisco
2018 Phase 1/Phase 2 NCT03538899 United States;
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Busulfan IV
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02629120 United States;
Busulfan test dose
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Busulfan, Cyclophosphamide, ATG, GCSF
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Busulfan, Fludarabine and ATG
Emory University
2004 Phase 1/Phase 2 NCT00228852 United States;
Busulfan, Fludarabine, ATG, TLI
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
C1 ESTERASE INHIBITOR (HUMAN)
Octapharma Pharmazeutika Produktionsges.m.b.H.
2020 Phase 2 EUCTR2019-001693-28-DE Belarus;Germany;Russian Federation;Ukraine;
C1 Esterase Inhibitor Human
Octapharma Pharmazeutika Produktionsges.m.b.H.
2020 Phase 2 EUCTR2019-001693-28-DE Belarus;Germany;Russian Federation;Ukraine;
C1 inhibitor
HAE Global Registry Foundation
2017 - NCT03828279 Italy;
C1 inhibitor concentrate
Sanquin
2005 Phase 2 NCT00119431 Netherlands;
C1-esterase inhibitor [recombinant] (C1-INH-R)
IMMUNOe Research Centers
2018 Phase 4 NCT03576469 United States;
CD3/CD19 neg allogeneic BMT
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 1/Phase 2 NCT03330795 United States;
CD3/CD19 negative allogeneic hematopoietic stem cells
Paul Szabolcs
2013 Phase 1/Phase 2 NCT01852370 United States;
CD34 Stem Cell Selection Therapy
Diane George
2013 Phase 1/Phase 2 NCT01966367 United States;
CD34+
Children's Hospital Medical Center, Cincinnati
2010 Phase 2 NCT01856582 United States;
CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT
National Institute of Allergy and Infectious Diseases (NIAID)
2012 Phase 1/Phase 2 NCT03315078 United States;
CD34+ cells transduced with ADA retrovir
National Human Genome Research Institute (NHGRI)
2001 Phase 1 NCT00018018 United States;
CD34+CELLS
Rocket Pharmaceuticals, Inc.
2020 Phase 1;Phase 2 EUCTR2020-000517-33-GB Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2018-002680-26-ES Spain;
CDZ173
NOVARTIS PHARMA SERVICES AG
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IT Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Novartis Pharma Services AG
2021 Phase 2;Phase 3 EUCTR2016-000468-41-FR Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2016-000468-41-GB Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-NL Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-CZ Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Novartis Pharmaceuticals
2015 Phase 2/Phase 3 NCT02435173 Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Pharming Technologies B.V.
- Phase 2;Phase 3 EUCTR2016-000468-41-DE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
CL20-i4-EF1a-h?c-OPT
St. Jude Children's Research Hospital
2016 Phase 1/Phase 2 NCT01512888 United States;
CT Scan
Koneti Rao
2008 Phase 1/Phase 2 NCT00605657 United States;
CUTAQUIG
Octapharma
2019 Phase 3 NCT03939533 United States;
CUVITRU
Baxalta now part of Shire
2018 - NCT03716700 Canada;
Campath -1H
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
Campath 1H
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
Campath, Fludarabine, Cyclophosphamide
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Catapresan 75, Tabletten
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Cell processing for TCRabeta+/CD19+ depletion
Michael Pulsipher, MD
2018 Phase 2 NCT03619551 United States;
Cell processing for TCRaß+/CD19+ depletion
Michael Pulsipher, MD
2018 Phase 2 NCT03619551 United States;
Chemotherapy, intrathecal chemotherapy, steroid therapy
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Chrono Super PID then Generic Syringe-Gammanorm
Octapharma
2015 Phase 4 NCT02503293 Australia;Germany;Italy;United Kingdom;
CliniMACS
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
CliniMACS® CD34 Reagent System cell sorter device
University of California, San Francisco
2018 Phase 1/Phase 2 NCT03538899 United States;
CliniMacs
St. Jude Children's Research Hospital
2016 Phase 1/Phase 2 NCT01512888 United States;
Clonidinhydrochlorid
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Collection of samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Conjugated pneumococcal vaccine (Prevenar)
Institute of Child Health
2006 Phase 3 NCT00656409 United Kingdom;
Continuous Glucose Monitor
Washington University School of Medicine
2020 - NCT04275479 United States;
Cryopreserved EFS-ADA LV transduced patient CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2018 Phase 1 EUCTR2018-000673-68-GB United Kingdom;
Cultured Thymus Tissue
M. Louise Markert
2010 - NCT01220531 United States;
Cultured Thymus Tissue Implantation (CTTI)
M. Louise Markert
2004 Phase 2 NCT00576836 United States;
Cultured Thymus Tissue for Implantation (CTTI)
M. Louise Markert
2005 Phase 1/Phase 2 NCT00579527 United States;
1991 Phase 2 NCT00576407 United States;
Cuvitru
Baxalta now part of Shire
2017 Phase 4 NCT03116347 Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
Cuvitru 200 mg/ml solution for subcutaneous injection
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Cyclophosphamide
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Capital Research Institute of Pediatrics
2015 - NCT03198195 -
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00358657 United States;
Graduate Schoool,Dept. of Community Pediatrics,Perinatal and Maternal Medicine,Tokyo Medical and Dental University
2015 - JPRN-UMIN000019532 Japan;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2012 - NCT01652092 United States;
2007 Phase 2/Phase 3 NCT00455312 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2019 Early Phase 1 NCT03910452 United States;
2015 Phase 1/Phase 2 NCT02629120 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Cyclophosphamide (Cytoxan)
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Cyclophosphamide 30
Columbia University
2002 Phase 2/Phase 3 NCT01019876 United States;
Cyclophosphamide 40
Columbia University
2002 Phase 2/Phase 3 NCT01019876 United States;
Cyclophosphamide Dose Level 1
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 2
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 3
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide Dose Level 4
Children's Hospital Los Angeles
2007 Phase 2 NCT02512679 -
Cyclophosphamide post transplant
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 1/Phase 2 NCT02282904 United States;
Cyclosporine
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
1997 Phase 1 NCT00008450 United States;
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Cyclosporins
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
DB289
Immtech Pharmaceuticals, Inc
2003 Phase 2 NCT00803933 Congo;
2001 Phase 2 NCT00802594 Angola;Congo;
DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
ERYDEL S.P.A.
2016 Phase 3 EUCTR2015-005241-31-IT Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
EryDel S.p.A.
2020 Phase 3 EUCTR2018-000338-36-NO Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
2020 Phase 3 EUCTR2018-000338-36-GB Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000338-36-ES Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000338-36-DE Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000338-36-BE Australia;Belgium;Germany;India;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2015-005241-31-NO Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005241-31-ES Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005241-31-DE Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005241-31-BE Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
- Phase 3 EUCTR2018-000338-36-PL Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
- Phase 3 EUCTR2015-005241-31-PL Australia;Belgium;Costa Rica;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
Daclizumab
M. Louise Markert
2005 Phase 1/Phase 2 NCT00579527 United States;
Danazol
Boston Children's Hospital
2009 Phase 1/Phase 2 NCT01001598 United States;
The University of Queensland
2021 Phase 2 NCT04638517 Australia;
Data collection
Paul Szabolcs
2020 - NCT04528355 United States;
Depletion in CD45RA graft donor
Assistance Publique - Hôpitaux de Paris
2016 Phase 2 NCT02737384 France;
Dexametasone Fosfato Sodico
ERYDEL S.P.A.
2016 Phase 3 EUCTR2015-005241-31-IT Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States;
Dexamethasone 21-dihydrogen phosphate
Universitätsklinikum Heidelberg
2006 Phase 3 EUCTR2005-003201-81-DE Germany;
Dexamethasone sodium phosphate (soluzione 25mg/ml)
ERYDEL S.P.A.
2021 Phase 3 EUCTR2018-000338-36-IT Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
Dexamethasone, procarbazine
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Dextrose, in Water
Grifols Therapeutics Inc.
2002 Phase 3 NCT00220766 Canada;United States;
Donor peripheral blood stem cells.
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 1/Phase 2 NCT02282904 United States;
Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
EDS-EP dose range of ~14-22 mg DSP/infusion
Erydel
2017 Phase 3 NCT02770807 Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
EDS-EP dose range of ~5-10 mg DSP/infusion
Erydel
2017 Phase 3 NCT02770807 Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States;
EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2012 Phase 1;Phase 2 EUCTR2010-024253-36-GB United Kingdom;
EF1aS-ADA lentiviral vector transduced patient CD34+ cells
Great Ormond Street Hospital for Children NHS Trust
2012 Phase 1;Phase 2 EUCTR2010-024253-36-GB United Kingdom;
EP2006 (Filgrastim)
Sandoz GmbH
2011 - EUCTR2011-001118-32-DE Germany;Sweden;
EZN-2279
Leadiant Biosciences, Inc.
2014 Phase 3 NCT01420627 United States;
Efficacy of Gammagard subcutaneously at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subcutaneously at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subcutaneously at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subdermally at Week 12
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subdermally at Week 24
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Efficacy of Gammagard subdermally at Week 36
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Eflornithine
Drugs for Neglected Diseases
2012 Phase 2/Phase 3 NCT01685827 Central African Republic;Congo;Congo, The Democratic Republic of the;
2004 Phase 3 NCT00146627 Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;
Eflornithine plus Nifurtimox combination therapy
Epicentre
2002 Phase 2/Phase 3 NCT00489658 Uganda;
Elapegademase-lvlr
Chiesi Farmaceutici S.p.A.
2019 - NCT03878069 United States;
Eltrombopag
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT04371939 Russian Federation;
Empagliflozin
Cliniques universitaires Saint-Luc
2019 Phase 4 EUCTR2018-004191-35-BE Belgium;
Hong Kong Children's Hospital
2021 - NCT04986735 -
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 1 NCT05078879 United States;
Estradiolvalerat
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Etoposide
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Etoposide, cytarabine, mercaptopurine
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
National Institute of Allergy and Infectious Diseases (NIAID)
2012 Phase 1/Phase 2 NCT01306019 United States;
FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
Fansidar (pyrimethamine and sulfadoxine)
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 1 NCT00013689 United States;
Fexinidazole
Drugs for Neglected Diseases
2019 Phase 2/Phase 3 NCT03974178 Malawi;Uganda;
2016 Phase 3 NCT03025789 Congo, The Democratic Republic of the;Guinea;
2015 Phase 1 NCT02571062 France;
2014 Phase 2/Phase 3 NCT02184689 Congo, The Democratic Republic of the;
2014 Phase 2/Phase 3 NCT02169557 Congo, The Democratic Republic of the;
2014 Phase 2 NCT02498782 Bolivia;
2012 Phase 2/Phase 3 NCT01685827 Central African Republic;Congo;Congo, The Democratic Republic of the;
2009 Phase 1 NCT00982904 France;
Fibrinogen (coagulation factorI)
CSL Behring GmbH
2011 - EUCTR2007-004088-22-DE Germany;Italy;
Fibrinogen Concentrate from Human Plasma
Biotest AG
2013 Phase 1;Phase 2 EUCTR2011-004154-25-IT Egypt;Germany;Italy;Lebanon;
Filgrastim
Fairview University Medical Center
2000 - NCT00006056 United States;
National Center for Research Resources (NCRR)
1994 Phase 2 NCT00004787 -
Filgrastim Hexal
Sandoz GmbH
2011 - EUCTR2011-001118-32-DE Germany;Sweden;
Filgrastim, Alemtuzumab
St. Jude Children's Research Hospital
2004 Phase 1 NCT00152100 United States;
Flebogamma DIF
Instituto Grifols, S.A.
2008 Phase 4 NCT00634569 United States;
Fludarabina Accord
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Fludarabine
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
2004 Phase 2 NCT00578643 United States;
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
Columbia University
2002 Phase 2/Phase 3 NCT01019876 United States;
Graduate Schoool,Dept. of Community Pediatrics,Perinatal and Maternal Medicine,Tokyo Medical and Dental University
2015 - JPRN-UMIN000019532 Japan;
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
2007 Phase 2/Phase 3 NCT00455312 United States;
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
National Center for Child Heath and Development
2018 Phase 1,2 JPRN-UMIN000030806 Japan;
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 1/Phase 2 NCT02282904 United States;
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
Fludarabine Phosphate
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00358657 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Fludarabine monophosphate
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Fludarabine phosphate
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2005 Phase 1 NCT00295971 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Fludarabine, Busulfan, Thymoglobulin
The Korean Society of Pediatric Hematology Oncology
2007 Phase 1/Phase 2 NCT00885833 Korea, Republic of;
Fludarabine, Melphalan, Thiotepa
St. Jude Children's Research Hospital
2005 Phase 1 NCT00160355 United States;
Fortecortin Inject 40 mg Amp.
Universitätsklinikum Heidelberg
2006 Phase 3 EUCTR2005-003201-81-DE Germany;
G-CSF
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
2014 Phase 2/Phase 3 NCT02231879 United States;
G-CSF for Conditioning before HSCT.
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2016 Phase 2 NCT03019809 Russian Federation;
G1XCG
Johann Wolfgang Goethe-University
2013 Phase 1;Phase 2 EUCTR2012-001725-26-DE Germany;
G1XCGD transduced CD34+ cells
GENETHON
2013 - EUCTR2012-000242-35-DE France;Germany;Switzerland;United Kingdom;
Genethon
2013 Phase 1;Phase 2 EUCTR2012-000242-35-GB France;Germany;Switzerland;United Kingdom;
GAMMAGARD LIQUID
Baxalta now part of Shire
2017 Phase 3 NCT03277313 United States;
GAMUNEX-C
Grifols Therapeutics Inc.
2011 Phase 4 NCT01465958 United States;
GTG003.08
GENETHON
- Phase 1;Phase 2 EUCTR2009-011152-22-FR France;
GVHD Prophylaxis
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
2015 Phase 2 NCT02579967 United States;
Gadolinium For abdomen
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Gadolinium For lower back
ASIS Corporation
2016 Phase 1/Phase 2 NCT02123615 United States;
Gammagard S/D (Solvent/Detergent)
Baxalta now part of Shire
2002 Phase 2 NCT00161993 Finland;Sweden;
Gammaglobulin
Federal University of São Paulo
2002 - NCT00661401 Brazil;
Gammanorm
Octapharma
2014 Phase 4 NCT02180763 France;
Gammanorm 165 mg/mL
Octapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria
2015 Phase 3;Phase 4 EUCTR2014-003746-27-GB Australia;Germany;United Kingdom;
2015 Phase 3;Phase 4 EUCTR2014-003746-27-DE Australia;Germany;Italy;United Kingdom;
Gammaplex
Bio Products Laboratory
2011 Phase 4 NCT01289847 Chile;Israel;United States;
Bio Products Laboratory Limited
- - EUCTR2011-005679-18-Outside-EU/EEA Chile;United States;
Gammaplex ()
Bio Products Laboratory
2014 Phase 3 NCT01963143 Hungary;United Kingdom;United States;
Gammaplex (Intravenous immunoglobulin)
Bio Products Laboratory
2006 Phase 3 NCT00278954 United States;
Gammaplex 10
Bio Products Laboratory
2014 Phase 3 NCT01963143 Hungary;United Kingdom;United States;
Bio Products Laboratory Limited
2014 Phase 3 EUCTR2013-002290-21-HU Hungary;United Kingdom;United States;
2014 Phase 3 EUCTR2013-002290-21-GB Hungary;Israel;United Kingdom;United States;
Gamunex-C
Grifols Therapeutics LLC
2020 Phase 3 NCT04561115 United States;
Gcsf
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT03547830 Russian Federation;
Gene Therapy Method for CGD
National Institute of Allergy and Infectious Diseases (NIAID)
1995 Phase 1 NCT00001476 United States;
Gene transfer
David Williams
2010 Phase 1/Phase 2 NCT01129544 United States;
Gene-Transduced Autologous CD34+ Stem Cells
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 1 NCT00028236 United States;
Generic Syringe then Chrono Super PID-Gammanorm
Octapharma
2015 Phase 4 NCT02503293 Australia;Germany;Italy;United Kingdom;
Genetically modified autologous blood stem cells
Johann Wolfgang Goethe-University
2013 Phase 1;Phase 2 EUCTR2012-001725-26-DE Germany;
Glycolic acid
University of Pennsylvania
2009 - NCT01289171 Botswana;
Glycosade
John Mitchell
2013 - NCT02054832 Canada;
Gold
Chengdu Women's and Children's Center Hospital
2021 Phase 0 ChiCTR2100043049 China;
Children's Hospital of Chongqing Medical University
2020 Phase 0 ChiCTR2000032139 China;
Gp91 Grans
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1 NCT05189925 United States;
Granulocyte colony stimulating factor (G-CSF)
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
HTLP
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 1;Phase 2 EUCTR2018-001029-14-FR France;
HUMAN NORMAL IMMUNOGLOBULIN (IV)
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Biotest AG
2017 Phase 3 EUCTR2015-003652-52-GB Germany;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-ES Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-DE Germany;Russian Federation;Spain;United Kingdom;United States;
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2010-023483-41-FR France;Hungary;
2011 - EUCTR2010-023483-41-HU Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
2009 - EUCTR2009-012036-32-FR France;
- - EUCTR2010-023483-41-Outside-EU/EEA Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
Haemocomplettan P
CSL Behring GmbH
2007 - EUCTR2006-006023-39-IT Italy;
Haemocomplettan(R) P 1g/2g
CSL Behring GmbH
2011 - EUCTR2007-004088-22-DE Germany;Italy;
Haplo BM with T cell depletion
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Haploidentical Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
2020 Phase 2 NCT04414046 United States;
Hematopoetic Stem Cell Transplantation
University of Pittsburgh
2012 - NCT03333200 United States;
Hematopoietic Stem Cell Transplant
Medical College of Wisconsin
2013 Phase 2 NCT01998633 Canada;United States;
Hematopoietic stem cell transplantation
St. Jude Children's Research Hospital
2005 Phase 1 NCT00160355 United States;
Hizentra
CSL Behring LLC
- Phase 4 EUCTR2016-003799-33-Outside-EU/EEA Canada;United States;
University of South Florida
2010 - NCT01354587 United States;
Hizentra®
CSL Behring
- - EUCTR2014-003609-14-Outside-EU/EEA Japan;
- - EUCTR2014-003608-61-Outside-EU/EEA Japan;
- - EUCTR2014-003409-13-Outside-EU/EEA Japan;
CSL Behring AG
2008 Phase 3 EUCTR2008-000830-30-GB France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
- - EUCTR2014-003607-30-Outside-EU/EEA United States;
- - EUCTR2014-003605-15-Outside-EU/EEA United States;
Horse -Anti-thymocyte
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
Human Fibrinogen Concentrate
Biotest AG
2013 Phase 1;Phase 2 EUCTR2011-004154-25-IT Egypt;Germany;Italy;Lebanon;
Human Immunglobulin G (IgG)
CSL Behring AG
2007 Phase 3 EUCTR2006-006745-13-GB France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-FR France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-ES France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-SE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-DE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
Human Immunoglobulin
KEDRION S.P.A
2021 Phase 3 EUCTR2020-001496-32-PT Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-SK Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-HU Hungary;Italy;Portugal;Russian Federation;Slovakia;
Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01412385 Austria;Germany;Hungary;Sweden;United Kingdom;
Human Normal Immunoglobulin G (IgG > purity)
CSL Behring AG
- - EUCTR2014-003772-23-Outside-EU/EEA United States;
Human Normal Immunoglobulin for Subcutaneous Administration
CSL Behring
2006 Phase 3 NCT00419341 United States;
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
CSL Behring
2007 Phase 3 NCT00542997 France;Germany;Italy;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
Human Normal Immunoglobulin for subcutaneous administration
LFB Biotechnologies
2014 - EUCTR2013-000620-34-GB France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-IT France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-HU France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-DE France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
Human T Lymphoid Progenitor (HTLP) injection
Assistance Publique - Hôpitaux de Paris
2020 Phase 1/Phase 2 NCT03879876 France;
Human normal immunoglobulin
UMC Utrecht
2021 Phase 4 EUCTR2021-005001-26-NL Netherlands;
Human normal immunoglobulin (IVIg)
Biotest AG
2005 - EUCTR2004-004465-15-HU Germany;Hungary;
2005 - EUCTR2004-004465-15-DE Germany;Hungary;
Human normal immunoglobulin (subcutaneous)
CSL Behring LLC
- Phase 4 EUCTR2016-003799-33-Outside-EU/EEA Canada;United States;
Human normal immunoglobulin for intravenous administration
LFB SA
2007 - EUCTR2007-001410-17-FR France;
Human normal immunoglobulin for intravenous use (IVIG)
Biotest AG
2010 - EUCTR2010-019249-25-HU Germany;Hungary;
2010 - EUCTR2010-019249-25-DE Germany;Hungary;
HyQvia 100 mg/ml solution for infusion for subcutaneous use
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Hydroxyurea
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
I10E
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2010-023483-41-FR France;Hungary;
2011 - EUCTR2010-023483-41-HU Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
- - EUCTR2010-023483-41-Outside-EU/EEA Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine;
IB 1001
IntraBio Ltd.
2019 Phase 2 EUCTR2018-004407-39-GB Germany;United Kingdom;United States;
IB1001
IntraBio Inc
2020 Phase 2 NCT03759678 Germany;Spain;United Kingdom;United States;
IntraBio Ltd
2020 Phase 2 EUCTR2018-004407-39-DE Germany;Spain;United Kingdom;United States;
IFN-gamma
National Institute of Allergy and Infectious Diseases (NIAID)
2010 Phase 4 NCT01147042 United States;
IGIV,
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
IGIV-C
Grifols Therapeutics LLC
2016 Phase 3 NCT02604810 Canada;United States;
IGNG
LFB BIOTECHNOLOGIES
2009 - EUCTR2009-012036-32-FR France;
LFB SA
2007 - EUCTR2007-001410-17-FR France;
IGSC
Grifols Therapeutics LLC
2021 Phase 4 NCT04566692 United States;
2016 Phase 3 NCT02806986 Australia;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 NCT02604810 Canada;United States;
IGSC daily push versus 2 times per week pump
Grifols Therapeutics LLC
2019 Phase 3 NCT03814798 United States;
IGSC daily push versus every 2 weeks pump
Grifols Therapeutics LLC
2019 Phase 3 NCT03814798 United States;
IGSC daily push versus once a week pump
Grifols Therapeutics LLC
2019 Phase 3 NCT03814798 United States;
IGSC infusion
Takeda
2021 Phase 3 NCT04842643 Japan;
IGSC,
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
IMMUNOGLOBULIN G
CSL Behring
2008 Phase 3 EUCTR2006-006745-13-PL France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
OCTAPHARMA AG
2012 - EUCTR2012-000792-16-HU Czech Republic;Germany;Hungary;
2012 - EUCTR2012-000792-16-DE Czech Republic;Germany;Hungary;
2012 - EUCTR2012-000792-16-CZ Czech Republic;Germany;Hungary;
Octapharma AG
- - EUCTR2011-005015-82-Outside-EU/EEA United States;
IMMUNOGLOBULINA UMANA NORMALE
KEDRION S.P.A
2020 Phase 3 EUCTR2020-001496-32-IT Hungary;Italy;Portugal;Slovakia;
IV treatment with IGSC,
Baxalta now part of Shire
2010 Phase 3 NCT01175213 United States;
IVIG
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
IVIG-PEG
Grifols Therapeutics LLC
2020 Phase 3 NCT04561115 United States;
Ibuprofen
IRCCS San Raffaele
2015 Phase 2 NCT03055247 Italy;
Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy;
IgG Next Generation
Biotest AG
2017 Phase 3 EUCTR2015-003652-52-GB Germany;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-ES Germany;Hungary;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003652-52-DE Germany;Russian Federation;Spain;United Kingdom;United States;
IgG Next Generation (BT595)
Biotest
2016 Phase 3 NCT02810444 Germany;Hungary;Russian Federation;Spain;United States;
IgHy10
University Hospital, Lille
2016 Phase 4 NCT02881437 France;
IgNextGen
CSL Limited
2007 Phase 3 NCT00391131 Australia;New Zealand;
IgPro10
CSL Behring KK
- Phase 3 EUCTR2016-001631-12-Outside-EU/EEA Japan;
IgPro20
CSL Behring
2017 Phase 4 NCT03033745 Canada;United States;
2008 Phase 3 NCT00751621 France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
2008 Phase 3 NCT00719680 United States;
2008 Phase 3 EUCTR2006-006745-13-PL France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
CSL Behring AG
2008 Phase 3 EUCTR2008-000830-30-GB France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;
2008 Phase 3 EUCTR2008-000830-30-FR France;Germany;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000830-30-SE France;Germany;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000830-30-ES France;Germany;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000830-30-DE France;Germany;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-GB France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-FR France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-006745-13-ES France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-SE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006745-13-DE France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
- - EUCTR2014-003607-30-Outside-EU/EEA United States;
CSL Behring AG (casa madre)
2007 - EUCTR2006-006745-13-IT France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
CSL Behring LLC
- Phase 4 EUCTR2016-003799-33-Outside-EU/EEA Canada;United States;
Immune Globulin Infusion (Human),
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01485796 United States;
Immune Globulin Intravenous (Human)
Grifols Therapeutics Inc.
2006 Phase 2 NCT00389324 Canada;United States;
Immune Globulin Intravenous (Human) Liquid, IVIG-SN™
Green Cross Corporation
2011 Phase 3 NCT01406470 Canada;United States;
Immune Globulin Intravenous (Human),
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01412385 Austria;Germany;Hungary;Sweden;United Kingdom;
2007 Phase 2/Phase 3 NCT00546871 United States;
2002 Phase 3 NCT00157079 United States;
Immune Globulin Intravenous (Human), Solution
Baxalta now part of Shire
2013 Phase 2/Phase 3 NCT01218438 Canada;United States;
Immune Globulin Intravenous (Human), TVR (Triple Virally Reduced) Solution
Baxalta now part of Shire
2002 Phase 2 NCT00161993 Finland;Sweden;
Immune Globulin Intravenous (IGIV)
Baxalta now part of Shire
2020 Phase 3 NCT04346108 Japan;
Immune Globulin Intravenous [Human], Caprylate/Chromatography Purified
Grifols Therapeutics Inc.
2002 Phase 3 NCT00220766 Canada;United States;
Immune Globulin Subcutaneos,
Baxter Innovations GmbH
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Immune Globulin Subcutaneous (Human) (SCIG)
CSL Behring
2010 Phase 3 NCT01199705 Japan;
Immune Globulin Subcutaneous (Human),
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01412385 Austria;Germany;Hungary;Sweden;United Kingdom;
Immune Globulin Subcutaneous (Human), , Caprylate/Chromatography Purified
Grifols Therapeutics Inc.
2017 Phase 3 EUCTR2015-003290-15-HU Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-GB Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-FR Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-ES Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-DE Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-CZ Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
- Phase 3 EUCTR2015-003290-15-PL Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
Immune Globulin Subcutaneous (Human), Caprylate/Chromatography Purified (IGSC )
Grifols Therapeutics Inc.
2017 Phase 3 EUCTR2015-003290-15-HU Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-GB Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-FR Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-ES Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-DE Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom;
2016 Phase 3 EUCTR2015-003290-15-CZ Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
- Phase 3 EUCTR2015-003290-15-PL Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom;
Immune Globulin Subcutaneous (Human), Solution
Baxalta now part of Shire
2013 Phase 2/Phase 3 NCT01218438 Canada;United States;
Immune Globulin Subcutaneous,
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Immune Globulin Subcutaneous, Solution (IGSC, )
Baxalta now part of Shire
2020 Phase 3 NCT04346108 Japan;
Immune globulin subcutaneous (Human)
CSL Behring
2011 Phase 3 NCT01461018 Japan;
2011 Phase 3 NCT01458171 Japan;
Immune globulin subcutaneous (human)
CSL Behring AG
2008 Phase 4 EUCTR2006-006522-25-GR Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-GB Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-ES Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-DE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-BE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
Immunglobulin (human)
CSL Behring AG
2007 - EUCTR2006-006522-25-IT Belgium;Germany;Greece;Italy;Spain;United Kingdom;
Immunoglobulin G
OCTAPHARMA AG
2010 - EUCTR2009-011434-10-DE Germany;
- - EUCTR2009-011434-10-Outside-EU/EEA United States;
Immunoglobulin G (Ig NextGen )
CSL Limited
2008 Phase 3 NCT00680446 Australia;New Zealand;
Immunoglobulin intravenous (human)
CSL Behring KK
- Phase 3 EUCTR2016-001631-12-Outside-EU/EEA Japan;
Immunoglobulins Intravenous (Human)
CSL Behring
2005 Phase 3 NCT00322556 United States;
2004 Phase 3 NCT00168025 -
2004 Phase 3 NCT00168012 -
Immunoglobulins, normal human
CSL Behring AG (casa madre)
2007 - EUCTR2006-006745-13-IT France;Germany;Italy;Poland;Spain;Sweden;United Kingdom;
Immunological diagnosis tests
University Hospital, Lille
2015 - NCT02972281 France;
Immunosuppression Only Conditioning
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
Immunosuppression Only Conditioning -Closed with amendment L
National Cancer Institute (NCI)
2015 Phase 2 NCT02579967 United States;
In vitro-treated peripheral blood stem cell transplantation
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
Increlex
National Institute of Allergy and Infectious Diseases (NIAID)
2007 Phase 1/Phase 2 NCT00490100 United States;
Infliximab
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Phase 1/Phase 2 NCT00325078 United States;
Infusion of autologous EFS-ADA LV CD34+ (OTL-101)
Orchard Therapeutics
2013 Phase 1/Phase 2 NCT01852071 United States;
Infusion of autologous EFS-ADA LV CD34+ cells
Great Ormond Street Hospital for Children NHS Foundation Trust
2012 Phase 1/Phase 2 NCT01380990 United Kingdom;
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1/Phase 2 NCT03765632 United Kingdom;
Orchard Therapeutics
2016 Phase 1/Phase 2 NCT02999984 United States;
Interferon-gamma
National Institute of Allergy and Infectious Diseases (NIAID)
1992 Phase 4 NCT00001317 United States;
Intratect
Biotest AG
2010 - EUCTR2010-019249-25-HU Germany;Hungary;
2010 - EUCTR2010-019249-25-DE Germany;Hungary;
2005 - EUCTR2004-004465-15-HU Germany;Hungary;
2005 - EUCTR2004-004465-15-DE Germany;Hungary;
Intravenous immunoglobulin infusion
Sanquin
2013 Phase 3 NCT01985373 Netherlands;
Intravenous infusion of transduced cells
Great Ormond Street Hospital for Children NHS Foundation Trust
2003 Phase 1/Phase 2 NCT01279720 United Kingdom;
Isolex 300i Magnetic Cell Selector
National Institute of Allergy and Infectious Diseases (NIAID)
1995 Phase 1 NCT00001476 United States;
Itraconazole
National Institute of Allergy and Infectious Diseases (NIAID)
1991 Phase 2 NCT00001280 United States;
Jardiance
Cliniques universitaires Saint-Luc
2019 Phase 4 EUCTR2018-004191-35-BE Belgium;
KIOVIG
Baxalta now part of Shire
2017 Phase 4 NCT03116347 Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
KIOVIG 100 mg/ml solution for infusion
Baxalta US Inc.
2019 Phase 4 EUCTR2016-003438-26-HU Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-SE Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-GB Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-FR Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-DK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
2017 Phase 4 EUCTR2016-003438-26-CZ Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
- Phase 4 EUCTR2016-003438-26-SK Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom;
Baxter Innovations GmbH
2012 - EUCTR2012-000481-38-GB Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
KIg10
KEDRION S.P.A
2021 Phase 3 EUCTR2020-001496-32-PT Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-SK Hungary;Italy;Portugal;Russian Federation;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-IT Hungary;Italy;Portugal;Slovakia;
2020 Phase 3 EUCTR2020-001496-32-HU Hungary;Italy;Portugal;Russian Federation;Slovakia;
KLH
National Institute of Allergy and Infectious Diseases (NIAID)
1999 Phase 2 NCT00001145 United States;
KVD824
KalVista Pharmaceuticals, Ltd.
2021 Phase 2 NCT05055258 Australia;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;Puerto Rico;United Kingdom;United States;
KVD824 300 mg Compresse a rilascio modificato
KalVista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD824 300 mg Modified Release Tablets
Kalvista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-HU Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-DE Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD824 hydrochloride
KalVista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
Kalvista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-HU Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-DE Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
KVD900
KalVista Pharmaceuticals, Ltd.
2022 Phase 3 NCT05259917 -
2019 Phase 2 NCT04208412 Austria;Czechia;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
KVD900 100 mg Film Coated Tablet
KalVista Pharmaceuticals Ltd
2019 Phase 2 EUCTR2018-004489-32-IT Austria;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-GB Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States;
KalVista Pharmaceuticals Ltd.
2019 Phase 2 EUCTR2018-004489-32-PL Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-NL Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-HU Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;
2019 Phase 2 EUCTR2018-004489-32-DE Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-AT Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
Kedrion IVIG
Kedrion S.p.A.
2021 Phase 3 NCT04944979 Hungary;Italy;Slovakia;
2019 Phase 3 NCT03961009 Canada;United States;
2012 Phase 3 NCT01581593 Canada;United States;
Kineret
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2015 Early Phase 1 NCT04136028 Russian Federation;
L-Arginin-hydrochlorid-einmolar Fresenius
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
L-fucose
Orpha Labs
2012 Phase 1/Phase 2 NCT03354533 -
LADICell
Rocket Pharmaceuticals, Inc.
2020 Phase 1;Phase 2 EUCTR2020-000517-33-GB Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2018-002680-26-ES Spain;
LDT
Progenity, Inc.
2015 - NCT02787486 United States;
LFB-IgSC
LFB Biotechnologies
2014 - EUCTR2013-000620-34-GB France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-IT France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-HU France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
2013 - EUCTR2013-000620-34-DE France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom;
Lemtrada
Karolinska Universitetssjukhuset
2018 Phase 2 EUCTR2018-001489-41-SE Sweden;United States;
Leniolisib
NOVARTIS PHARMA SERVICES AG
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IT Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Novartis Pharma Services AG
2021 Phase 2;Phase 3 EUCTR2016-000468-41-FR Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2016-000468-41-GB Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2016-000468-41-IE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-NL Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
2016 Phase 2;Phase 3 EUCTR2016-000468-41-CZ Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Pharming Technologies B.V.
- Phase 2;Phase 3 EUCTR2016-000468-41-DE Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States;
Lentiviral G1XCGD Gene Therapy
University of California, Los Angeles
2015 Phase 1/Phase 2 NCT02234934 United States;
Lentiviral vector transduced CD34+ cells
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1 NCT03601286 United Kingdom;
MABTHERA - 2 FIALE 100 MG 10 ML
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
MBM-01
Matrix Biomed, Inc.
2021 Phase 2 NCT04887311 United States;
MCTLs
Catherine Bollard
2014 Phase 1 NCT02510404 United States;
MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
MYELOSTIM
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO + SIRINGA PRERIEMPITA SOLVENTE 1 ML
Orchard Therapeutics (Europe) Ltd
2010 Phase 1;Phase 2 EUCTR2009-017346-32-IT Italy;
MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
MabThera
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Mavorixafor
X4 PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001153-10-IT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
X4 Pharmaceuticals
2020 Phase 1 NCT04154488 United States;
2019 Phase 3 NCT03995108 Australia;Austria;Denmark;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United States;
X4 Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-001153-10-PL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-NL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-HU Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-GB Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-FR Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-ES Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-DE Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-AT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001153-10-DK Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d
Epicentre
2001 Phase 3 NCT00330148 Uganda;
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d
Epicentre
2001 Phase 3 NCT00330148 Uganda;
Melphalan
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Metformin
NHS Tayside
2016 Phase 4 NCT02733679 United Kingdom;
Methotrexate
Fairview University Medical Center
2000 - NCT00006056 United States;
2000 - NCT00006054 United States;
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Methylprednisolone
Fairview University Medical Center
2000 - NCT00006054 United States;
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
Methylprednisolone or Prednisolone
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Miltenyi CliniMACS
St. Jude Children's Research Hospital
2004 Phase 1 NCT00152100 United States;
Miltenyi CliniMACS selection system
St. Jude Children's Research Hospital
2005 Phase 1 NCT00160355 United States;
Mozobil
IRCCS San Raffaele
2015 Phase 2 NCT03055247 Italy;
Mozobil 20mg/mL vial (injectable solution for subcutaneous use)
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Mozobil 20mg/mL vial (injectable solution, subcutaneous use)
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Mozobil,
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Mycophenolate mofetil
Boston Children's Hospital
2012 Phase 2 NCT01659606 Norway;Sweden;United States;
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Mycophenolate mofetil (MMF)
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Myeloablative Conditioning-Closed with amendment L
National Cancer Institute (NCI)
2015 Phase 2 NCT02579967 United States;
Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Myelostim
IRCCS San Raffaele
2015 Phase 2 NCT03055247 Italy;
N-Acetyl-L-Leucine
IntraBio Ltd.
2019 Phase 2 EUCTR2018-004407-39-GB Germany;United Kingdom;United States;
NDV-3A
National Institute of Allergy and Infectious Diseases (NIAID)
2016 Phase 2 NCT02996448 United States;
Nanogam 100 mg/ml
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
Nanogam® 50 mg/ml
Sanquin Blood Supply Foundation
2013 - EUCTR2012-005727-32-NL Netherlands;
Neopterin
Institut de Recherche pour le Developpement
2017 - NCT03112655 Congo, The Democratic Republic of the;
NewGam
OCTAPHARMA AG
2010 - EUCTR2009-011434-10-DE Germany;
- - EUCTR2009-011434-10-Outside-EU/EEA United States;
Octapharma
2011 Phase 3 NCT01313507 United States;
2010 Phase 3 NCT01012323 United States;
Newnorm
Octapharma
2021 Phase 3 NCT04640142 Germany;Poland;Slovakia;Ukraine;United States;
Octapharma Pharmazeutika Prod.Ges.m.b.H
2021 Phase 1;Phase 3 EUCTR2020-004734-37-DE Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
- Phase 1;Phase 3 EUCTR2020-004734-37-SK Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
- Phase 1;Phase 3 EUCTR2020-004734-37-PL Czechia;Germany;Poland;Russian Federation;Slovakia;Ukraine;United States;
Nicotinamide ribonucleoside
University Hospital, Akershus
2019 Phase 2 NCT04870866 Norway;
Nifurtimox
Drugs for Neglected Diseases
2012 Phase 2/Phase 3 NCT01685827 Central African Republic;Congo;Congo, The Democratic Republic of the;
2004 Phase 3 NCT00146627 Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;
Universidad Autónoma de Bucaramanga
2015 Phase 2/Phase 3 NCT02369978 Colombia;
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
Epicentre
2001 Phase 3 NCT00330148 Uganda;
Nifurtimox-Eflronithine Combination Treatment (NECT)
Drugs for Neglected Diseases
2009 Phase 4 NCT00906880 Congo;
None
KalVista Pharmaceuticals Ltd
2019 Phase 2 EUCTR2018-004489-32-GB Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States;
KalVista Pharmaceuticals Ltd.
2019 Phase 2 EUCTR2018-004489-32-PL Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-NL Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-HU Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;
2019 Phase 2 EUCTR2018-004489-32-DE Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004489-32-AT Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00358657 United States;
1997 Phase 1 NCT00008450 United States;
Normal human immunoglobulin G
CSL Behring AG
2008 - EUCTR2008-000830-30-SE France;Germany;Spain;Sweden;United Kingdom;
Norovirus -specific T-cell (NST) therapy
Children's National Research Institute
2020 Phase 1 NCT04691622 United States;
Noxafil 40 mg/ml oral solution
Radboud University Nijmegen Medical Centre
2009 - EUCTR2008-004518-28-GB Netherlands;United Kingdom;
2008 - EUCTR2008-004518-28-NL Netherlands;United Kingdom;
NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
OCTA-C1-INH
Octapharma Pharmazeutika Produktionsges.m.b.H.
2020 Phase 2 EUCTR2019-001693-28-DE Belarus;Germany;Russian Federation;Ukraine;
OCTAGAM 50 mg/ml oldatos infúzió
OCTAPHARMA AG
2012 - EUCTR2012-000792-16-HU Czech Republic;Germany;Hungary;
ORENCIA® 125 mg solution for injection in pre-filled syringe
Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
2016 Phase 2 EUCTR2015-002491-24-DE Germany;
OTL-101
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
Orchard Therapeutics
2019 Phase 2/Phase 3 NCT04140539 United States;
OTL-103 Dispersion for Infusion
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Octagam
OCTAPHARMA AG
2012 - EUCTR2012-000792-16-DE Czech Republic;Germany;Hungary;
Octapharma
2009 Phase 3 NCT00811174 Austria;
Octapharma AG
2010 Phase 3 EUCTR2007-002611-27-GB France;Germany;United Kingdom;
2010 - EUCTR2007-002611-27-FR France;United Kingdom;
2008 - EUCTR2007-002611-27-DE France;Germany;United Kingdom;
Octanorm
Octapharma
2017 Phase 3 NCT03988426 Russian Federation;
2016 Phase 3 NCT03907241 Canada;United States;
2016 Phase 3 NCT02627300 Canada;United States;
2014 Phase 3 NCT01888484 Canada;Czech Republic;Czechia;Hungary;Poland;Russian Federation;Slovakia;United States;
Octapharma Pharmazeutika Prod.Ges.m.b.H
2017 Phase 1;Phase 3 EUCTR2013-003877-87-SK Canada;Czech Republic;Hungary;Poland;Russian Federation;Slovakia;United States;
2015 Phase 3 EUCTR2013-003877-87-PL Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
2014 Phase 3 EUCTR2013-003877-87-HU Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
2014 Phase 1;Phase 3 EUCTR2013-003877-87-CZ Canada;Czech Republic;Hungary;Poland;Slovakia;United States;
Omalizumab (Xolair)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 1 NCT00260702 United States;
Other hematological Agents
Orchard Therapeutics Ltd.
2019 Phase 3 EUCTR2018-003842-18-IT Italy;
Ovastat 1000 (Treosulfan injection)
medac Gesellschaft fuer klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-AT Austria;Czech Republic;Germany;Italy;Poland;
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-DE Austria;Czech Republic;Germany;Italy;Poland;
medac GmbH
2015 - EUCTR2013-005508-33-IT Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-PL Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 1000 mg, powder for solution for infusion
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-CZ Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 5000 (Treosulfan injection)
medac Gesellschaft fuer klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-AT Austria;Czech Republic;Germany;Italy;Poland;
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-DE Austria;Czech Republic;Germany;Italy;Poland;
medac GmbH
2015 - EUCTR2013-005508-33-IT Austria;Czech Republic;Germany;Italy;Poland;
2014 Phase 2 EUCTR2013-005508-33-PL Austria;Czech Republic;Germany;Italy;Poland;
Ovastat 5000 mg, powder for solution for infusion
medac Gesellschaft für klinische Spezialpräparate mbH
2014 Phase 2 EUCTR2013-005508-33-CZ Austria;Czech Republic;Germany;Italy;Poland;
PEG-ADA ERT
Orchard Therapeutics
2016 Phase 1/Phase 2 NCT02999984 United States;
2013 Phase 1/Phase 2 NCT01852071 United States;
PEG-interleukin-2
Mount Sinai School of Medicine
1997 - NCT00004695 -
PHA-022121
Pharvaris Netherlands B.V.
2022 Phase 2 NCT05047185 Canada;United Kingdom;United States;
2021 Phase 2 NCT04618211 Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Pharvaris Netherlands BV
2022 Phase 2 EUCTR2021-000227-13-PL Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2022 Phase 2 EUCTR2021-000227-13-BG Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-PL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-NL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-HU Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
2021 Phase 2 EUCTR2020-003445-11-DE Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-BG Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2020-003445-11-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
- Phase 2 EUCTR2020-003445-11-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PHVS416
Pharvaris Netherlands BV
2022 Phase 2 EUCTR2021-000227-13-PL Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2022 Phase 2 EUCTR2021-000227-13-BG Bulgaria;Canada;Germany;Israel;Poland;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-PL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-NL Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-HU Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
2021 Phase 2 EUCTR2020-003445-11-DE Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003445-11-BG Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2020-003445-11-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
- Phase 2 EUCTR2020-003445-11-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PID
Children's Hospital of Chongqing Medical University
2020 Phase 0 ChiCTR2000032139 China;
PNEUMO 23
Inserm
2009 - EUCTR2007-003235-23-FR France;
PREVENAR
Inserm
2009 - EUCTR2007-003235-23-FR France;
PROLEUKIN® S
Universitätsklinikum Freiburg
2016 Phase 2 EUCTR2015-003369-27-DE Germany;
PSRS11.EFS.IL2RG.pre* retroviral vector transduce
Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
2010 Phase 1;Phase 2 EUCTR2007-000684-16-GB United Kingdom;
PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells
Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
2010 Phase 1;Phase 2 EUCTR2007-000684-16-GB United Kingdom;
PTH 1-34
National Institute of Dental and Craniofacial Research (NIDCR)
2006 Phase 3 NCT00395538 Austria;Italy;United States;
Palifermin
National Institute of Allergy and Infectious Diseases (NIAID)
2012 Phase 1/Phase 2 NCT03315078 United States;
2012 Phase 1/Phase 2 NCT01306019 United States;
Pantoprazolo 20 mg gastro-resistant tablets
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Peg-Ada
Great Ormond Street Hospital for Children NHS Foundation Trust
2018 Phase 1/Phase 2 NCT03765632 United Kingdom;
2012 Phase 1/Phase 2 NCT01380990 United Kingdom;
Pentamidine
Immtech Pharmaceuticals, Inc
2003 Phase 2 NCT00803933 Congo;
Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
Roswell Park Cancer Institute
2017 Phase 2 NCT03333486 United States;
Peripheral blood stem cell transplantation
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Peripheral blood stem cells
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02629120 United States;
Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
National Institute of Allergy and Infectious Diseases (NIAID)
2006 Early Phase 1 NCT00394316 United States;
Pioglitazone
Children's Hospital of Fudan University
2017 Phase 1/Phase 2 NCT03080480 China;
NHS Tayside
2016 Phase 4 NCT02733679 United Kingdom;
Plerixafor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT03547830 Russian Federation;
National Institute of Allergy and Infectious Diseases (NIAID)
2014 Phase 2/Phase 3 NCT02231879 United States;
Ospedale San Raffaele
2015 - EUCTR2015-002356-27-IT Italy;
Plerixafor for Conditioning before HSCT.
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2016 Phase 2 NCT03019809 Russian Federation;
PnCJ PPS
Institut National de la Santé Et de la Recherche Médicale, France
2009 Phase 2 NCT01489618 France;
Pneumovax® (pneumococcal polysaccharide vaccine)
Sheba Medical Center
2010 - NCT01075438 Israel;
Polyclonal IgG
Federico II University
2010 - NCT03534479 Italy;
Posaconazole (PSZ)
Radboud University
2009 Phase 2 NCT00799071 Netherlands;United Kingdom;
Prednisone
Fairview University Medical Center
2000 - NCT00006054 United States;
Prevenar
Great Ormond Street Hospital
2005 Phase 4 EUCTR2005-004122-70-GB United Kingdom;
Prevenar® (7-valent pneumococcal conjugate vaccine)
Sheba Medical Center
2010 - NCT01075438 Israel;
Privigen
CSL Behring KK
- Phase 3 EUCTR2016-001631-12-Outside-EU/EEA Japan;
Privigen®
CSL Behring AG
- - EUCTR2014-003772-23-Outside-EU/EEA United States;
Progynova 21 mite
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Promacta
Weill Medical College of Cornell University
2009 Phase 2 NCT00909363 United States;
Prometic's Immune Globulin Intravenous
Prometic Biotherapeutics, Inc.
2016 Phase 3 NCT02269163 United States;
Purified Vero Cell Vaccine)
Chulalongkorn University
2015 Phase 4 NCT02490956 Thailand;
Pyrimethamine
National Institute of Allergy and Infectious Diseases (NIAID)
2003 Phase 1 NCT00065390 United States;
R-hIL-18BP
AB2 Bio Ltd.
2019 Phase 3 EUCTR2018-003297-27-DE Canada;Germany;United States;
- Phase 3 EUCTR2018-003199-10-DE Canada;Germany;United States;
RAG1 LV CD34+ cells
Leiden University Medical Center
2020 Phase 1;Phase 2 EUCTR2019-002343-14-NL Netherlands;
RI-002
ADMA Biologics, Inc.
2014 Phase 3 NCT01814800 United States;
RP-L201
Rocket Pharmaceuticals Inc.
2019 Phase 1/Phase 2 NCT03812263 Spain;United Kingdom;United States;
2019 Phase 1 NCT03825783 Spain;
Rocket Pharmaceuticals, Inc.
2020 Phase 1;Phase 2 EUCTR2020-000517-33-GB Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2018-002680-26-ES Spain;
Rabbit anti-thymocyte globulin
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Ranitidine
National Institute of Allergy and Infectious Diseases (NIAID)
2007 Phase 2 NCT00527878 United States;
Recombinant Human Hyaluronidase (rHuPH20)
Baxter Innovations GmbH
2012 - EUCTR2012-000481-38-GB Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
Recombinant human hyaluronidase
Baxalta now part of Shire
2011 Phase 2/Phase 3 NCT01485796 United States;
Nishizawa Atsushi
2022 Phase 3 JPRN-jRCT2031210457 Japan;
Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Baxalta now part of Shire
2008 Phase 3 NCT00814320 Canada;United States;
Recombinant human hyaluronidase + immune globulin intravenous
Baxalta now part of Shire
2006 Phase 1/Phase 2 NCT00782106 United States;
Reduced Intensity Conditioning
National Cancer Institute (NCI)
2018 Phase 2 NCT03663933 United States;
2015 Phase 2 NCT02579967 United States;
Reduced Intensity Preparative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Reduced Toxicity Ablative Regimen
Masonic Cancer Center, University of Minnesota
2014 - NCT02179359 United States;
Retroviral SF71-gp91phox transduced CD34+ cells
Johann Wolfgang Goethe University Hospitals
2004 Phase 1/Phase 2 NCT00564759 Germany;
Retrovirus-mediated gene transfer
David Williams
2011 Phase 1/Phase 2 NCT01410825 United States;
RhuCD40L
National Institute of Allergy and Infectious Diseases (NIAID)
1999 Phase 2 NCT00001145 United States;
Rifaximin
Oslo University Hospital
2013 Phase 4 NCT01946906 Norway;
Rimiducid
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
2014 Phase 2 NCT02065869 Germany;Italy;Spain;United Kingdom;United States;
Rituximab
National Center for Child Heath and Development
2018 Phase 1,2 JPRN-UMIN000030806 Japan;
Rituximab (RTX) and Azathioprine (AZA)
Medical College of Wisconsin
2016 Phase 2 NCT02789397 -
Rivogenlecleucel
Bellicum Pharmaceuticals
2017 Phase 1/Phase 2 NCT03733249 Italy;Saudi Arabia;United Kingdom;
Romiplostim
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019 Phase 2 NCT04371939 Russian Federation;
2012 - NCT04350164 Russian Federation;
SC treatment with IGSC, with rHuPH20 followed by IV/IGSC, only (safety)
Baxalta now part of Shire
2010 Phase 3 NCT01175213 United States;
SC treatment with IGSC, with rHuPH20 followed by SC/IGSC, only (safety)
Baxalta now part of Shire
2010 Phase 3 NCT01175213 United States;
SCID screening
Nantes University Hospital
2014 - NCT02244450 France;
SCYX-7158
Drugs for Neglected Diseases
2012 Phase 1 NCT01533961 France;
STA-5326
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 1 NCT00263237 United States;
STRIMVELIS
Orchard Therapeutics
2018 - NCT03232203 Italy;
SUBCUVIA
Baxter Innovations GmbH
2012 Phase 2;Phase 3 EUCTR2010-019459-23-BE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2010-019459-23-NL Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-SE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2011 - EUCTR2010-019459-23-DE Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-HU Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-GB Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2010-019459-23-AT Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom;
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States;
Fred Hutchinson Cancer Research Center
2006 Phase 2 NCT00358657 United States;
Imai Kohsuke
2022 Phase 2 JPRN-jRCT2031210309 Japan;
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT04370795 United States;
2019 Early Phase 1 NCT03910452 United States;
2015 Phase 1/Phase 2 NCT02629120 United States;
2014 Phase 1/Phase 2 NCT02282904 United States;
University of California, San Francisco
2014 Phase 2 NCT02177760 United States;
Sodium chloride
AB2 Bio Ltd.
2017 Phase 3 NCT03113760 Canada;Germany;United States;
Somatic gene-therapy by X-CGD
Johann Wolfgang Goethe-University
2013 Phase 1;Phase 2 EUCTR2012-001725-26-DE Germany;
Somatotropin
Goethe-Universität Frankfurt/Main
2009 - EUCTR2009-015739-34-DE Germany;
Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
Johann Wolfgang Goethe University Hospitals
2010 Phase 4 NCT01052623 Germany;
Stelara (ustekinumab)
National Institute of Allergy and Infectious Diseases (NIAID)
2015 Phase 1/Phase 2 NCT02199496 United States;
Stem Cell Infusion
Baylor College of Medicine
2004 Phase 2 NCT00578643 United States;
Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
2015 - NCT02162420 United States;
Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
2012 - NCT01652092 United States;
2007 Phase 2/Phase 3 NCT00455312 United States;
Stem cell infusion
Baylor College of Medicine
2007 Phase 1/Phase 2 NCT00579137 United States;
Masonic Cancer Center, University of Minnesota
2002 Phase 2/Phase 3 NCT00176852 United States;
Stem cell transplant
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
St. Jude Children's Research Hospital
2004 Phase 1 NCT00152100 United States;
Strimvelis
Orchard Therapeutics (Europe) Ltd
2017 Phase 4 EUCTR2017-001731-39-IT Italy;Switzerland;Turkey;
Subgam
Bio Products Laboratory
2015 Phase 3 NCT01884311 United States;
Suspension of autologous CD34+cells transduced with the G1XCGD viral vector
GENETHON
2013 - EUCTR2012-000242-35-DE France;Germany;Switzerland;United Kingdom;
Genethon
2013 Phase 1;Phase 2 EUCTR2012-000242-35-GB France;Germany;Switzerland;United Kingdom;
T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 3 NCT00023192 United States;
TAK-771
Takeda
2022 Phase 3 NCT05150340 Japan;
TBX-1400
Taiga Biotechnologies, Inc.
2021 Phase 1 NCT02860559 Israel;
TCR alfa beta T cell depletion
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2012 Phase 2/Phase 3 NCT02327351 Russian Federation;
TYF-IL-2Rg gene-modified autologous stem cells
Shenzhen Geno-Immune Medical Institute
2017 Phase 1/Phase 2 NCT03217617 China;
Tabelecleucel
Atara Biotherapeutics
2021 Phase 2 NCT04554914 Austria;Belgium;France;Italy;Spain;United Kingdom;United States;
2016 - NCT02822495 United States;
Tablets Fexinidazole
Drugs for Neglected Diseases
2011 Phase 1 NCT01483170 France;
Tacrolimus
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
2006 Phase 2 NCT00358657 United States;
M. Louise Markert
2010 - NCT01220531 United States;
2005 Phase 1/Phase 2 NCT00579527 United States;
Roswell Park Cancer Institute
2012 Phase 2 NCT01529827 United States;
Tacrolimus (Tacro)
National Cancer Institute (NCI)
2020 Phase 2 NCT04339777 United States;
Tadekinig alfa
AB2 Bio Ltd.
2018 Phase 3 NCT03512314 Canada;Germany;United States;
2017 Phase 3 NCT03113760 Canada;Germany;United States;
Thalidomide
Kawai Toshinao
2017 Phase 2-3 JPRN-jRCT2031200236 Japan;
National Center for Child Heath and Development
2017 - JPRN-UMIN000029324 Japan;
2012 - JPRN-UMIN000009370 Japan;
Therapeutic allogeneic lymphocytes
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
There is no recommended INN
Great Ormond Street Hospital for Children NHS Trust
2017 Phase 2 EUCTR2017-001275-23-GB United Kingdom;
Thiotepa
Paul Szabolcs
2014 Phase 2 NCT01962415 United States;
St. Jude Children's Research Hospital
2021 Phase 1/Phase 2 NCT03597594 United States;
University of California, San Francisco
2005 Phase 1 NCT00295971 United States;
Thiotepa--escalated dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Thiotepa--single daily dose
University of Florida
2018 Phase 1/Phase 2 NCT03513328 United States;
Thymafalsin
Erasmus MC
2022 Phase 2 EUCTR2021-003327-15-NL Netherlands;
Thymus Tissue for Transplantation
M. Louise Markert
2002 Phase 1 NCT00579709 United States;
Thymus/Parathyroid Transplantation
M. Louise Markert
2005 Phase 1 NCT00566488 United States;
To be confirmed
Kalvista Pharmaceuticals Ltd
2021 Phase 2 EUCTR2021-000136-59-HU Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-DE Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
2021 Phase 2 EUCTR2021-000136-59-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States;
Total Body Irradiation
Masonic Cancer Center, University of Minnesota
2007 Phase 2/Phase 3 NCT00455312 United States;
Total lymphoid irradiation
Masonic Cancer Center, University of Minnesota
2000 Phase 2/Phase 3 NCT00176878 United States;
Traditional treatment of CGD and TB
Children's Hospital of Fudan University
2019 Phase 2/Phase 3 NCT03984890 China;
Transduced Lymphocytes
National Human Genome Research Institute (NHGRI)
1990 - NCT00001255 United States;
Transplant Conditioning with Mobilization Only
University of California, San Francisco
2010 Phase 2 NCT01182675 United States;
Transplant Conditioning with Mobilization and Alemtuzumab
University of California, San Francisco
2010 Phase 2 NCT01182675 United States;
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Washington University School of Medicine
2013 Phase 2 NCT01821781 United States;
Treosulfan
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2020 Phase 2 NCT04400045 Russian Federation;
Fred Hutchinson Cancer Research Center
2022 Phase 2 NCT04965597 United States;
medac GmbH
2015 Phase 2 NCT02349906 Austria;Czech Republic;Czechia;Germany;Italy;Poland;
Triheptanoin
The University of Queensland
2022 Phase 2 NCT04513002 Australia;
Umbilical cord blood transplantation
University of California, San Francisco
2005 Phase 2 NCT00301834 United States;
2000 Phase 1/Phase 2 NCT00305708 United States;
Unrelated BM with T cell depletion
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Unrelated PBSC with T cell depletion
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Unrelated cord blood
Neena Kapoor, M.D.
2007 Phase 1/Phase 2 NCT02127892 United States;
Ustekinumab
National Institute of Allergy and Infectious Diseases (NIAID)
2018 Phase 1/Phase 2 NCT03366142 United States;
VM106
Helixmith Co., Ltd.
2007 Phase 1/Phase 2 NCT00778882 Korea, Republic of;
Valacyclovir
National Institute of Allergy and Infectious Diseases (NIAID)
2000 Phase 3 NCT00031486 Canada;Sweden;United Kingdom;United States;
Verorab® (PVRV
Chulalongkorn University
2015 Phase 4 NCT02490956 Thailand;
Vigantol
Karolinska University Hospital
2010 Phase 1/Phase 2 NCT01131858 Sweden;
Vinblastine, vincristine, prednisone, daunorubicin
St. Jude Children's Research Hospital
2002 - NCT00187057 United States;
Vitamin B3
Radboud University
2019 Phase 2 NCT03962114 Netherlands;
Vitamin D3
Children's Hospital of Fudan University
2019 Phase 2/Phase 3 NCT03984890 China;
Vivaglobin
CSL Behring
2007 Phase 4 NCT00520494 Belgium;Canada;Germany;Italy;Spain;
CSL Behring AG
2008 Phase 4 EUCTR2006-006522-25-GR Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-GB Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 Phase 4 EUCTR2006-006522-25-ES Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-IT Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-DE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006522-25-BE Belgium;Germany;Greece;Italy;Spain;United Kingdom;
X4P-001
X4 PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001153-10-IT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
X4 Pharmaceuticals
2016 Phase 2 NCT03005327 Australia;United States;
X4 Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-001153-10-PL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-NL Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-HU Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-GB Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-FR Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-ES Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-DE Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001153-10-AT Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001153-10-DK Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
XELJANZ (tofacitinib)
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1/Phase 2 NCT05104723 United States;
Xifaxan
Oslo University hospital
2013 - EUCTR2013-000883-27-NO Norway;
Zadaxin
Erasmus MC
2022 Phase 2 EUCTR2021-003327-15-NL Netherlands;
Zarzio
Sandoz GmbH
2012 Phase 4 EUCTR2011-001118-32-SE Germany;Sweden;
Zoledronate
Department of Pediatrics, Tokyo Medical and Dental University
2014 - JPRN-UMIN000013102 Japan;